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ABSTRACT 
SYNTHESIS, CHARACTERIZATION, AND EVALUATION OF METAL 
COMPLEXES FOR SELECTIVE TARGETING AND ANTI-PROLIFERATIVE 
EFFECT ON CANCER CELLS AND THEIR HYDROGEN EVOLUTION 
CATALYTIC PROPERTIES 
Nicholas Vishnosky 
November 19, 2018 
Bis-thiosemicarbazones (BTSC) and their metal chelates have properties that are 
useful in several different scientific fields. These systems have already received attention 
in major fields of biology and engineering. Hydrogen evolution reaction (HER) catalysts 
need to be cheap and operate under minimal overpotentials with a long lifetime. The 
treatment of cancer requires, novel agents that have potent cytotoxic activity against 
cancer cells while displaying minimal side effects. In this dissertation the modular 
synthesis of these bis-thiosemicarbazone systems is utilized to regulate the redox 
chemistry for employment in the desired sector of chemistry. The ligand and metal 
chelates synthesized were characterized via cyclic voltammetry, NMR, UV-visible 
spectroscopy, FT-IR, EPR, and single crystal X-ray crystallography. The first generation 
replaced the pendent amine functionality of BTSCs with an alkoxy group. This 
replacement allowed for the structure to retain its physical characteristics that make these 
systems of interest in biological settings. However the change in functional group allows 
for tuning of the reduction potential, which is crucial for their activity. The copper 
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diacetyl-bis(4-methylthiosemicarbazonato) (CuATSM) analog lays 250 mV more anodic 
for its CuII/I couple. 
 Immobilization of NiATSM (2), NiATSDM (28), and NiATSM-F6 (29) on a 
glassy carbon electrode surface revealed that after reductive cycling, 200-300 cycles, 
improved the overpotentials of 2 and 28 by 250 mV from 700 mV to 450 mV. The lack 
of a dramatic effect for 29, is due to solid state interactions between molecules and 
electrode surface. Raman spectroscopy and SEM reveal that 29, does not remain on the 
electrode surface, whereas 2 and 28 undergo dynamic rearrangement to improve overall 
performance. 
 A combination of both the pendant amine and alkoxy functionalities gave rise to 
the a new BTSC analog which chelated Ni, Cu and Zn. The electrochemical 
characterization revealed the copper chelates to have reduction potentials around 0.950 V 
CuII/I. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays 
showed high selectivity and potency with 50% growth inhibitory (GI50) concentrations 
of 0.09 and 2.0 μM for carcinogenic and healthy cell lines respectively. Further the 
National Cancer Institute (NCI) 60 profile demonstrates that the copper chelate is 
effective against a wide variety of cancer types. 
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CHAPTER I 
INTRODUCTION 
1.1 Scope of Dissertation 
 This dissertation describes a series of three studies on the synthesis, 
characterization, and various applications of N2S2 chelates related to the well-known bis-
thiosemicarbazone (BTSC) diacetyl-bis(4-methylthiosemicarbazone), H2ATSM. These 
studies include: 1) the synthesis and characterization of a new class of N2S2 chelates and 
their Cu(II) complexes; 2) the synthesis and application of nickel(II) BTSCs as 
heterogeneous catalysts for the hydrogen evolution reaction (HER); 3) the synthesis and 
evaluation of hybrid N2S2 chelates and their metal complexes as anti-cancer therapeutics. 
A comprehensive list of the 29 N2S2 compounds synthesized and evaluated in this 
dissertation can be found in Figure 1-1. 
New ligands and metal complexes developed in these studies were characterized 
by nuclear magnetic resonance (1H NMR and 13C NMR), Fourier-transform infrared (FT-
IR), and UV-Vis spectroscopies, mass spectrometry (ESI-MS), elemental analysis, single 
crystal x-ray crystallography, and cyclic voltammetry. Additionally, copper (II) complexes 
were characterized by electron paramagnetic resonance (EPR) spectroscopy. For 
compounds evaluated as heterogeneous HER catalysts additional characterization 
techniques were employed. These include linear sweep voltammetry (LSV) for complexes 
deposited on the electrode surface, Raman spectroscopy, scanning electron microscopy 
(SEM), and electrical impedance frequency response analysis (FRA). Compounds 
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investigated as anti-cancer therapeutics were subjugated to dose response analysis from 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Compounds 
19 and 21 were screened by the National Cancer Institute (NCI) against a set of 60 cell 
lines to examine potency against a standardized set of a cell lines and cancer types. 
 
Figure 1-1. Numbering scheme for all complexes.  
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 Chapter 1 provides an overview of the dissertation and introduces previous 
implementations of metal BTSC complexes in diagnostic imaging, anti-cancer 
therapeutics, and homogeneous hydrogen evolution catalysis. Chapter 2 specifies the 
experimental conditions, such as synthetic methodologies, yields, and characterization 
techniques for the complexes in this dissertation. This chapter also describes conditions 
used to determine electrochemical data, homogeneous catalysis conditions, and 
heterogeneous catalysis characterization. Chapter 3 describes the syntheses and 
characterization of a new class of N2S2 chelates related to BTSCs and their Cu(II) 
complexes. The six new N,Nʹ-bis(alkylthiocarbamate)butane-2,3-diimine chelates 
incorporate alkoxy alkyl chains derived from primary and secondary alcohols in place of 
the extensively studied pendant amines. The reduction potential of the Cu(II) complexes is 
tuned through the incorporation of the alkoxy functional group while maintaining the 
structural integrity that confers biological effects of BTSCs. Crucially, the data learned 
from this system allows for greater modulation of the ligand framework to tune the redox 
chemistry for either HER or anti-cancer. Chapter 4 focuses on the immobilization of three 
nickel (II) BSTC complexes on the glassy carbon electrodes as heterogeneous HER 
catalysts. These studies revealed a high dependence on surface morphology and solid state 
interactions that led to an improved electrode contact to reduce overpotential. Further, these 
nickel (II) BTSC complexes were not covalently linked to the electrode surface which 
allowed for dynamic reorganization on the electrode surface. Despite not being covalently 
linked, the complexes displayed robust activity over extended cycling. In Chapter, 5 the 
anti-cancer activity of new asymmetric chelates related to BTSCs and their metal 
complexes are discussed. It was observed from the MTT assays and electrochemistry that 
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there is a clear effect of structure on the compound’s anti-cancer activity. The reduction 
potentials illuminated features that conferred the selectivity for cancer cells compared to 
the healthy cells. Lastly, Chapter 6 contains concluding thoughts and future directions to 
the research in Chapters 3 – 5.  
1.2 Synthesis of BSTCs and Radioimaging Applications 
A class of compounds that has been applied in varying fields are 
thiosemicarbazides, RNHCSNHNH2. The thiosemicarbazide family has been well studied 
in areas such as tuberculosis treatments,1-2 anti-cancer activity,3-5 and metal absorbents.6 
These wide ranging abilities of the thiosemicarbazide family stem from its modular 
synthesis,7 which enables alteration of the molecule to suit the needs of a given application. 
Furthermore, the hydrazine functionality of the thiosemicarbazide is capable of undergoing 
a condensation reaction with a dione to generate bis-thiosemicarbazones (BTSC).8-9 The 
identity of the dione used can be varied to generate an extensive library of ligands that 
chelate a vast variety of metals.8,10-21 
 Like their thiosemicarbazide precursors, BTSCs have been extensively studied for 
applications across multiple disciplines of science, such as the treatment of 
neurodegenerative diseases,22-26 selective imaging of hypoxia,21,27-33 and as catalysts for 
the hydrogen evolution reaction (HER).10,12,34-35 The overarching similarity in these various 
applications is the accessibility of the reduction potential of the metal complex.16 For 
example, the HER requires a catalyst for the reduction of protons and hypoxia imaging 
relies on a complex that changes oxidation state under low oxygen conditions, where cells 
inherently are in a more reducing environment than normoxic conditions. Thus the ability 
to tune the reduction potential of a compound is paramount to the success in these fields.  
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 Overall the synthetic methodology for BTSCs involves the condensation of a 
thiosemicarbazide with a dione. The manner of the condensation can be either symmetric, 
Figure 1-2A, or non-symmetric, Figure 1-2B. The symmetric condensation maintains 
equivalent R groups from the thiosemicarbazide, but allows for variation in the dione R 
groups. The prototypical example of this is pyruvaldehyde bis(N4-methyl-
thiosemicarbazonato) (H2PTSM).
36-37 The non-symmetric condensation route allows for a 
finer tuning technique of either solubility, redox potential, or structure effects. For 
example, Que et al.32 exploited this methodology to attach a –CH2CF3 functionality for 
enhanced selectivity in cancer cell imaging.32  
 
Figure 1-2. Modular synthesis of symmetric condensation (A) and asymmetric condensation (B) 
of BTSCs 
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The modulation of reduction potential through variation of the BTSC ligand 
framework is exemplified by comparison of CuATSM and glyoxal bis(N4-methyl-
thiosemicarbazonato) copper(II) (CuGTSM), Figure 1-3. The only structural difference 
between these two complexes is the backbone moiety in which CuATSM has a 2,3-
butylene bridge whereas CuGTSM has an ethylene linker. The difference in electron donor 
ability of these substituents has a dramatic effect on the reduction potential. The CuII/I 
couple for CuATSM occurs at –1.11 V vs. ferrocenium/ferrocene (Fc+/Fc0), whereas the 
CuII/I potential for CuGTSM is observed 160 mV more anodic at –0.95 V.38 This difference 
in potential is the reason for the different biological activity of these two compounds. Both 
CuATSM and CuGTSM have been evaluated for hypoxia imaging via radiolabeling with 
either 64Cu or 62Cu. The more difficult to reduce CuATSM is found to be selectively 
retained in only hypoxic cells. The retention is based on the generation of a charged 
complex that only occurs in hypoxic cell, which prevents diffusion of the Cu from the 
cell.30 However, the more easily reduced CuGTSM, is reduced and retained in both 
normoxic and hypoxic cells.30 This finding has led to the synthesis of a variety of 
derivatives in efforts to enhance the selectivity for hypoxia imaging. The majority of these 
compounds focused on functionalizing the pendant amine to enhance imaging. 
 
Figure 1-3. Structures of CuATSM (left) and CuGTSM (right). 
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 As described above, the general synthetic methodology for BTSCs employs a 
condensation of a thiosemicarbazide with a dione. The desired thiosemicarbazide can be 
synthesized from the corresponding isothiocyanate and hydrazine.7 This synthetic route 
lends itself for various amine derivatives to be incorporated into the ligand framework. The 
modifications to the ligand framework are focused on tuning reduction potential or 
enhancement of radioimaging. Modifications to increase uptake of the radiolabeled 
compound include incorporation of the octa-peptide, octreotide, to the ligand framework.33 
Modifications to tune the reduction potential of the complex include incorporation of an 
alyll functionalitiy15 or a pyrollidine.39 Transamination by using 4,4-dimethyl-3-
thiosmeicarbazide can be employed to further modify the ligand framework by displacing 
the tertiary amine with the desired primary amine. This route has been particularly useful 
in the development of non-radiolabeled active imaging molecules.40 Using this route Emily 
Que and co-workers32 notably incorporated a –CH2CF3 functionality off one or both 
pendant amines that led to Cu complexes with an anodic shift of 70 mV per -CH2CF3 group. 
Upon entering a hypoxic environment, the mono –CH2CF3 substituted CuATSM derivative 
was reduced by one electron from a paramagnetic, d9 CuII to a diamagnetic, d10 CuI. The 
latter compounds can be readily observed by 19F MRI due to the absence of paramagnetic 
broadening that render the Cu2+ complexes unobservable. Additionally, the kinetic lability 
of CuI promotes dissociation from the ligand framework adding to the image enhancement. 
The CuII/I potential for the di –CH2CF3 substituted CuATSM derivative is similar to that of 
CuGTSM and it is too anodic for application in hypoxia imaging. The more anodic 
reduction potential of CuGTSM and related complexes makes them attractive candidates 
for other applications including cancer therapeutics.  
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1.3 Cancer and BTSCs 
 Recently, both CuGTSM and CuATSM were evaluated for their activity against 
prostate cancer cells.38 CuGTSM displayed a lower LD50 (1.5 μM) than CuATSM (7.0 
μM) for the treatment of PC-3 cells. The activity of CuGTSM was attributed to an increase 
of bioavailable copper, which induces apoptosis much like the related 2-keto-3-ethoxy-
butyraldehydebis(thiosemicarbazonato) (KTS) Cu(II) complex.41 To examine this, the cell 
culture was treated with the known copper chelator tetrathiomolybdate (TTM). The 
chelator affected the potency of CuGTSM, but that of CuATSM remained unchanged. This 
result was confirmed by using a metal responsive element (MRE)-luciferase reporter. 42-43 
 Although in vitro studies provide crucial insight to potential therapies, application 
in vivo is crucial for the further development of a therapy. Using the TRAMP transgenic 
prostate cancer mouse model,44 both CuGTSM and CuATSM were investigated for their 
viability in vivo. Weighing of the genitourinary tracts showed a 70% reduction in tumor 
weight relative to the control when the mice were treated with CuGTSM. Further 
evaluation using the Suttie scoring system45 showed marked improvement with the 
CuGTSM treatment. It should be noted that this treatment was not without side effects. 
Mice treated with CuGTSM suffered from kidney toxicity caused by copper accumulation. 
 Pharmokinetic experiments determined that the chelated copper does not exchange 
with other metals in vivo.38 Further, ZnGTSM was examined as a potential anti-cancer 
agent, but was found to be inactive in agreement with previous reports.41,46 It was 
previously established that the copper ionophores clioquinol and disulfiram inhibit 
proteasomal chymotrypsin-like activity.47-49 To examine if CuGTSM exhibited similar 
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effects, the expression and subcellular localization of the X-linked inhibitor of apoptosis 
protein (XIAP) was monitored.49-51 Inhibition of proteasomal activity causes the 
localization of XIAP to move from the cytoplasm to the nucleus. Following treatment with 
CuGTSM, the XIAP was found to have been localized in the nucleus, confirming the 
inhibitions of proteasomal activity by CuGTSM. This result of XIAP localization in the 
nucleus was not observed following treatment with CuATSM. 
 The previous work done on CuGTSM by Cater et al.38 prompted the exploration for 
new copper BTSCs with more anodic redox couples than CuATSM for therapeutic 
purposes. Palanimuthu et al.39 focused on the incorporation of cyclic moieties into the 
pendant amine. The cyclic moieties were synthesized by the condensation of 4-
pyrrolidinyl-3-thiosemicarbazide with benzil or butanedione or the condensation of 4-
methyl-4-phenylthiosemicarbazide with glyoxal. These compounds were then evaluated 
for anti-cancer activity using MTT assays of the carcinogenic cell lines SiHa (cervical 
cancer), MCF-7 (breast cancer), PC-3 (prostate cancer), A-2780 (ovarian cancer), and 
HepG2 (hepatocellular liver cancer). The results from the MTT assays showed CuGTSC 
as the most potent compound. The CuII/I couple of CuGTSC was found to be 400 mV more 
anodic than CuATSM. The compound obtained from condensation of 4-pyrrolidinyl-3-
thiosemicarbazide with benzyl had a CuII/I couple 240 mV more anodic than CuATSM but 
displayed no effect on carcinogenic cell lines other than HepG2. This result indicates that 
reduction potential is not the only determinant in the anti-cancer activity. 
 To confirm cellular uptake and location of copper from CuGTSC and CuGSTC·HCl 
in to the cancer cells, ICP-OES was employed by Palanimuthu and co-workers to show 
that the copper was preferentially located in the cytoplasm rather than the nucleus after 
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treatment with CuGTSC or CuGSTC·HCl. The protonated complex, CuGSTC·HCl, is 
expected to equilibrate with the buffer during evaluation to generate CuGTSC in situ. It 
remains unclear as to why the observed results for both neutral and protonated differ. 
Further measurement of the lipophilicity of CuGTSC and CuGSTC·HCl was conducted by 
a modification of the common water and 1-octanol partition coefficient study.52 
Chloroform was employed in place of octanol due to solubility issues and the conversion 
factor Poctanol = (1.343 + logPchloroform)/1.126.
53 The measurements revealed a correlation of 
cytotoxicity with their lipophilicity, with the more lipophilic CuGTSC requiring a lower 
does to achieve cytotoxicity. The compounds were then investigated to examine the 
mechanism of apoptosis induction. 
Several previous reports observed that CuBTSCs were capable of inhibiting DNA 
synthesis.54-57 This is in contrast to the reactive oxygen species (ROS) mediated anti-cancer 
activity of the mono-TSCs.54,58 Using the [3H]thymidine incorporation assay, it was found 
CuGTSC (Figure 1-4) did inhibit DNA synthesis. Further, in a competition with ethidium 
bromide, the binding affinities of CuGTSC and CuGSTC·HCl for DNA were determined. 
These results showed that CuGSTC·HCl (i.e., charged species) displayed a higher binding 
affinity for DNA than the neutral CuGTSC, indicating an electrostatic component to the 
interaction. Lastly, the results from viscosity experiments pointed to intercalation as the 
mode of binding.  
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Figure 1-4. CuGTSC structure. 
 In attempt to elucidate the mechanism related to inhibition of DNA synthesis, DNA 
cleavage and topoisomerase inhibition59-62 studies were performed. Using supercoiled 
pBR322 plasmid DNA and gel electrophoresis, the amount of cleaved DNA could be 
measured. A Human Topo IIα kit was employed to measure the inhibition of 
topoisomerase. The majority of the BTSC Cu complexes investigated did not display a 
large amount of cleavage or inhibition, including CuGTSC. The protonated CuGSTC·HCl 
derivative however, showed 86% cleavage and 90% inhibition, significantly higher than 
CuGTSC which had values of 24% and 52%, respectively. Further the cleavage of DNA 
was not mediated by ROS since the same result was found when run under in argon 
atmosphere.  
The interesting result of the structure activity relationship displayed by 
Palanimuthu was advanced by Palma and co-workers.63 Incorporating cyclic amines as the 
pendant amine of the BTSC resulted in reduction potential closer to CuATSM than 
CuGTSM. While this modification led to enhanced cytotoxicity, there was decreased 
selectivity for carcinogenic versus healthy cells. The observed increase in cytotoxicity was 
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attributed to the increased lipophilicity conferred by the cyclic amine increasing cellular 
uptake relative to CuATSM. Although cellular uptake was increased, the efflux rate of the 
compound with cyclic amines remained unchanged compared to CuATSM.64 It should be 
noted that the presence of a pendant secondary amine may lead to efflux via multidrug 
resistant protein one (MDR-1) for BTSC complexes.65  
For anti-cancer activity with BTSCs the metal employed has generally been copper. 
Recently, a series of cobalt(III) containing BTSCs11 was evaluated for their anti-cancer 
properties. As observed with Cu, the easier to reduce species were found to be the most 
potent. However, this class of compounds displayed relatively poor activity. Interestingly, 
when copper was scrubbed from culture medium with tetrathiomolybdate,66-68 the 
anticancer activity was further diminished, indicating a copper dependence. Further studies 
have not been performed to elucidate if this result is an effect of metal exchange or other 
Cu-mediated processes.  
1.4 Hydrogen Evolution and BTSCs 
Whereas cancer applications of BTSCs focus primarily on modulation of the 
reduction potential, HER catalysts require an understanding of ligand basicity. The US 
energy economy is largely been based on non-renewable resources, Figure 1-5.69 A major 
drawback of renewable energy sources such as solar and wind is the need to store energy 
for peak usage. The use of H2 as an energy carrier is considered green as the combustion 
of H2 produces water rather than greenhouse gasses as a product. However, for a whole 
process to be considered green, the production of H2 also needs to be ecologically friendly. 
The two industrially employed techniques of H2 production are steam methane reformation 
and coal gasification, both of which generate CO2 as a byproduct. The cleanest way to 
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produce hydrogen is by splitting water. Crucially, the reaction is non-spontaneous and 
requires a thermodynamic potential of 1.23 V. However, any system employed will have 
to supply additional energy to overcome the overpotential. Overpotential results from an 
activation barrier due to electron transfer barriers and diffusion effects. The ideal catalyst 
will operate at a minimal overpotential and be capable of economic scale up. 
 
Figure 1-5. Distribution of energy consumption in the US.69 
Recently Haddad et al. evaluated the H2ATSM ligand and ZnATSM as 
homogeneous HER catalysts.10 This was the first evaluation of BTSCs as possible HER 
catalysts and metal-free HER catalysis. The Zn complex was a viable HER catalysts in 
both acetonitrile and methanol, whereas the ligand was active only in methanol. The cyclic 
voltammogram of H2ATSM displayed one irreversible reduction at –2.1 V vs Fc
+/Fc in the 
absence of acid. Titration of acetic acid to a 3 mM ligand solution lead to an increase of 
current at -2.1 V until the acid reached 9.8 mM, at which the current plateaued. The 
turnover frequency (TOF) from the ligand to produce hydrogen was 1320 s-1 with an 
overpotential of 1.43 V. 
  
14 
 
The Zn complex performed better compared to the ligand in methanol. It should be 
noted that the Zn complex displayed no reduction events in the absence of acid in the cyclic 
voltammogram. Upon addition of acid, a catalytic peak was observed at –1.7 V, implying 
the first step of HER with ZnATSM is protonation. Acetic acid was added up to 12.0 mM, 
upon which the increase in current plateaued. Under these conditions, the TOF was found 
to be 1170 s-1, slightly lower than the free ligand. However, the overpotential of the Zn 
derivative in methanol was 0.756 V, which is 0.674 V lower than with the ligand alone. 
With an identical environment, a bulk electrolysis over the course of 2.5 hours gave a 
turnover number (TON) of 37 with a Faradaic efficiency of 85%. Interestingly in 
acetonitrile, the acid plateau occurred at 23 mM, giving an order of magnitude larger TOF 
of 11,700 s-1 but with a larger overpotential of 1.074 V. This large difference could 
potentially arise from a change in the properties of the solvents after addition of acid such 
as the dielectric constant. No studies were performed to measure the change of the physical 
properties of the solvents. The catalytic event was found to be at –2.3 V which is close to 
the free ligand reduction even without acid. 
The mechanistic studies revealed that the reaction is first order with respect to both 
ZnATSM and acetic acid.70 Kinetic isotope effect (KIE) experiments71-73 in acetonitrile, 
using deuterated acetic acid gave a value of 1.2, which is unique from those previously 
reported for HER electrocatalysts, insinuating an unprecedented mechanism of action. 
Combining simulations and density functional theory (DFT) calculations, two plausible 
mechanisms were determined. It is crucial to note that both pathways involve ligand 
centered radical coupling, require protonation as the first step, and require the cooperation 
of two complexes, Scheme 1-1.  
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Scheme 1-1. ZnATSM possible HER mechanisms. 
In an effort to improve the performance of the ATSM framework as a HER catalyst, 
Haddad et al. evalutaed CuATSM.34 The hypothesis being that the metal center could assist 
in the ligand reactivity. Prior to any acid additions a reversible reduction was observed at 
-1.20 V vs Fc+/Fc0 in acetonitrile, which is assigned to the CuII/I couple. Addition of acid 
led to an anodic shift of this event to –0.95 V, indicative of protonation prior to catalysis. 
This was later confirmed via spectrophotometric titrations and simulations. Addition of 
acid also led to a new cathodic peak at -1.70 V. Interestingly, at lower acid concentrations, 
the mechanism is second order with respect to acid. However, as concentrations increase, 
it becomes independent of acid concentration at 0.269 M. This change in acid dependency 
is indicative of a pre-equilibrium step prior to H2 release. The TOF for this system was 
found to be 10,000 s-1, with an overpotential 0.8 V, which is 0.3 V lower than ZnATSM.10 
Identical studies were performed in DMF, however the catalytic activity was significantly 
diminished as compared to studies in acetonitrile. It is hypothesized that this is due to the 
strong hydrogen bonding nature of DMF. KIE experiments gave a value of 7.54 which is 
consistent with that observed for a ligand centered rhenium thiolate HER catalyst.74 
Further, it was revealed that one proton was involved in the rate determining step. From 
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the combination of experimental results, digital simulations of cyclic voltammogram (CV) 
data, and DFT calculations a mechanism was proposed, Scheme 1-2. Each step of the 
mechanism was confirmed by DFT to be the lowest energy state. While both Zn and 
CuATSM undergo a CECE mechanism, chemical protonation (C) followed by reduction 
(E), the copper proceeds through a monomeric pathway in contrast with the zinc. Another 
difference between these two systems was the development of a film on the working 
electrode following bulk electrolysis for the copper derivative but not for the zinc. Thus, it 
is impossible to rule out any heterogeneous effects of HER catalysis for the copper 
complex. 
 
Scheme 1-2. Mechanism for H2 evolution from CuATSM. 
With a wide variety of ligands available, Straistari and co-workers synthesized and 
studied the HER catalysis of a NiATSM derivative.35 This particular derivative replaced 
the methyl off the pendant amine with para-anisole, Figure 1-6. This was then used to 
chelate nickel giving a complex with reduction events at -1.57 and -2.10 V in DMF. With 
the addition of trifluoroacetic acid, a new reduction event occurred at -1.23 V. This was 
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attributed to HER catalysis and reached acid saturation at 100 mM. Using foot-of-the-wave 
analysis, a TOF was calculate to be 3080 s-1.  
 
Figure 1-6. Structure of NiATSM para-anisole. 
Bulk electrolysis at -1.73 V gave a TON of 21 and a Faradaic efficiency of 80%. 
Interestingly, control experiments did not reveal any formation of a film or nanoparticles 
during the course of the bulk electrolysis. Further mechanistic studies were carried out 
using DFT computations. The first reduction was assigned as ligand centered and the 
subsequent reduction was found to be metal centered. When a proton is added after the first 
reduction, the site of protonation was found to be the imino nitrogen of the ligand 
framework. Reduction after this protonation remained on the nickel, as previously 
established in the absence of acid. A NiIII-H hydride is produced after the second 
protonation event prior to H2 release. This novel mechanism was the first to use the metal 
center directly to evolve H2 for the BTSC class of compounds. The overpotential of this 
novel NiBTSC system was lower than the previously reported ATSM derivatives studied 
by Haddad et al.10,34 
The results from Straistari et al.35 led Jain et al. to evaluate the electrocatalytic 
behavior of NiATSM.75 The cyclic voltammograms displayed two reversible reductions at 
-1.83 and -2.45 vs Fc+/Fc in acetonitrile. These values for NiATSM are cathodically shifted 
to those of the para-anisole derivative reported by Straistari et al.35 Upon addition of acetic 
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acid, a catalytic peak was observed at -2.35 V and reached plateau after the addition of 12.6 
mM. This corresponded to a TOF of 4,200 s-1, an overpotential of 0.53 and a TON of 48 
after 4 hours. Trifluoroacetic acid was also used as an acid, while there was an anodic shift 
in the catalytic peak to -2.26 V, the overall performance diminished. The corresponding 
TOF, overpotential, and TON were 1,300 s-1, 0.67 V and 24. The same trend was observed 
when DMF was used as a solvent. Overall, the performance of the catalyst in DMF was 
lower. As previously mentioned this is caused by the hydrogen bonding of DMF. 
Mechanistic studies were performed on NiATSM, including concentration 
dependence studies, which revealed the reaction is first order with respect to the catalyst. 
There was no evidence of the formation of a film or nanoparticles. Spectrophotometric 
titrations displayed no protonation of the complex without prior reduction, in agreement 
with previous reports. The experimentally determined KIE value was inverse 1, which is 
consistent with the formation of a metal hydride. Combining these experimental results 
with DFT computations a mechanism was postulated. A ligand centered reduction occurs 
prior to protonation at the hydrazine nitrogen. The second reduction occurs on the metal 
center resulting in a metal hydride. This hydride intermediate is then capable of reacting 
with a proton in solution to evolve H2. Overall, the mechanism is ECEC. The mechanism 
is slightly different from that proposed by Straistari et al. for the para-anisole nickel 
complex (Figure1-6) as the first protonation occurs on the hydrazino nitrogen for NiATSM, 
whereas it is reported to occur on the imino nitrogen by Straistari et al.35 
Straistari and co-workers continued to examine the effect of the chelated metal on 
overall performance of the catalyst.12 The same para-anisole BSTC ligand was used to 
prepare the palladium complex. This is the first example of a later row transition metal 
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being employed with the BTSC ligand framework as a HER catalyst, however still 
remaining in the same family as nickel. Two reduction events are observed in the cyclic 
voltammogram in DMF, at potentials similar to the nickel derivative at -1.55 and -2.07 V. 
Following the reported methods for the nickel complex the centers of the reduction were 
determined using DFT. The reductive events were again found to first occur on the ligand 
and then on the metal, like the previous nickel systems.35,76 These results were further 
corroborated by calculation of the reduction potentials.  
The palladium system was then evaluated for its viability as a HER catalyst. 
Trifluoroacetic acid was added until saturation occurred at 100 mM. As the previously 
described nickel system is proposed to operate via ECEC, so is the palladium.35,76 DFT 
calculations were carried out to confirm this, along with spectrophotometric titrations that 
showed that the complex did not protonate upon the addition of trifluoroacetic acid without 
first undergoing a reduction. Interestingly, the first protonation event, while still ligand 
centered was found to occur on the hydrazino nitrogen as in CuATSM. The full HER 
mechanism is much like that of CuATSM involving the radical coupling of two ligand 
centered hydrogens, Scheme 1-2. 
A drawback of homogenous catalysis is the lack of long term stability and relatively 
large overpotentials. Heterogeneous catalysts generally offer a longer lifetime, but current 
ones are more expensive as they generally employ precious metals. The current standard 
for heterogeneous HER catalysis is a platinum electrode which operates at nearly no 
overpotential. While a multitude of work has been done on developing more cost efficient 
heterogeneous catalysts, there has yet to be any implementation of BTSCs on an electrode 
surface. As described earlier, CuATSM even under homogeneous conditions generated a 
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film on the electrode surface. Zhang et al. expanded upon this by drop-casting various 
BTSCs on a glassy carbon surface.77  
The ligand frameworks that were examined were ATSM and ATSP (Figure 1-7) as 
well as their copper and zinc chelates. Using scanning electron microscopy (SEM), all 
catalysts were evaluated before and after reductive cycling. It was apparent in all cases that 
after reductive cycling the film from the deposited catalyst was roughened by the evolution 
of hydrogen. In the cases of the ligand this meant a uniform film became reorganized and 
in the metal complexes, microcrystals became more amorphous.  
 
Figure 1-7. Structure of CuATSP. 
To confirm stability of the film after deposition on the working electrode, XPS was 
employed. For both frameworks, the ligand and copper complex were found to remain 
intact on the electrode surface. The zinc derivatives however were found to demetallate 
during the reductive cycling; the ligand remained intact though. This was also confirmed 
by UV-visible spectroscopy, in which after reductive cycling the zinc compounds 
electronic spectra were identical to that of the free ligand indicating they were no longer 
zinc chelates. 
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It should be noted that various loading amounts were required to achieve optimum 
performance for each system. Overall the best system was found to be copper derivatives, 
with an overpotential of 0.774 V and 0.745 V for CuATSM and CuATSP, respectively. 
While this is not a marked improvement from the homogeneous system of the 0.8 V 
overpotential for CuATSM,34 the immobilization of these compounds on the electrode 
surface displayed longevity of over 25 hours. One technique that has yet to be fully 
exploited is the generation of carbon paste electrodes with BTSCs. Zhang et al. showed 
that the synthesis of such an electrode with CuATSM led to a dramatic decrease in the 
overpotential to 0.531 V. 
1.5 Summary 
Overall BTSCs represent a versatile class of ligands suitable for numerous 
applications. The synthetic methodology lends itself to be varied in a multitude of locations 
to generate an extensive library of compounds. This modular synthesis dovetails with the 
need to fine tune the redox activity for the diverse applications in which these systems are 
employed. Applications that exploit the redox activity and ease of synthesis include 
hydrogen evolution catalysis, radioimaging, and therapeutics. In this dissertation, the 
library of BTSCs and structurally related derivatives, including a hybrid system, are 
expanded and explored for their use in heterogeneous HER and anti-cancer activity.
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CHAPTER II 
EXPERIMENTAL 
2.1 Physical Methods  
Elemental analyses were performed by Midwest Microlab (Indianapolis, IN). The 
electronic spectra were measured in quartz cuvettes (1 cm pathlength) using an Agilent 
8453 diode array spectrometer. Mass spectrometry (ESI-MS, positive mode) was 
performed by the Regenerative Medicine Research Center at the West China Hospital, 
Sichuan University, Chengdu, China or the Laboratory for Biological Mass Spectrometry 
at Texas A&M University, or MALDI-TOF at the University of Louisville. X-band 
electronic paramagnetic resonance (EPR) spectra were collected on powder samples at 
room temperature using a Bruker EMX (Bruker, Billerica, MA) spectrometer and 
simulated using EasySpin (MATLAB, version 5.2.23).78 The infrared spectra were 
recorded on a Thermo Nicolet 360 FT-IR spectrophotometer with ATR attachment 
(Thermo Fisher, Waltham, MA). NMR spectra were obtained on Varian 400 MHz 
spectrometer at 25 °C. X-ray crystallographic studies were performed by Dr. Mark 
Mashuta at the Department of Chemistry, University of Louisville on an Agilent 
Technologies/Oxford Diffraction Gemini CCD diffractometer (Agilent Technologies, 
Santa Clara, CA) .  
2.2 Electrochemical Measurements  
Homogeneous electrochemical data were collected using a Gamry Interface 1000E 
Potentiostat/Galvanostat/ZRA to perform all cyclic voltammetry (CV) experiments using 
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glassy carbon working electrode (diameter = 6.5 mm, surface area = 0.07 cm2), a 
platinum wire counter electrode, and Ag/AgCl reference electrode, with the exception of 
DCM which employed a silver wire as the reference electrode. All reported potentials are 
referenced versus ferrocenium/ferrocene (Fc+/Fc0). The working electrode was polished 
with alumina slurry prior to use. Both the working and counter electrode were washed with 
water, ethanol, acetone and sonication in working solvent (15 min) prior to use.  All CV 
experiments were performed under an inert atmosphere (either N2 or Ar) in a three-neck 
electrochemical cell that was washed and dried overnight prior to use. 
For CV measurements a working solvent was selected and a 0.1M of 
tetrabutylammonium hexafluorophospate was added. This was then degassed for 15 min 
by sparging the working solvent with either argon or nitrogen. The solvent was scanned 
over the full window to ensure no contaminants were present. The compound of interest 
was then added and the system was then purged with argon or nitrogen for another 15 
minutes to ensure no oxygen was present. The CVs of the complex could then be recorded. 
After completion of the CV experiment, a small quantity of ferrocene was added to act as 
an internal standard. For HER catalysis evaluation, glacial acetic acid was added, after 
which the solution was sparged with either nitrogen or argon to ensure a consistent 
concentration of acid. The system was allowed to rest after bubbling to ensure the reaction 
was diffusion controlled. 
 Heterogeneous evaluation of the activities of 2, 28, and 29 for HER was carried out 
in a three-electrode glass electrochemical cell (RDE/RRDE cell without water jacket, Pine 
Research, Durham, NC) with 0.5 M H2SO4 (VWR, ACS grade) in twice-deionized 
millipore water (18.2 Ωcm). A graphite rod (Pine Research), in a protective fritted glass 
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tube (Pine Research), was used as the counter electrode. Ag/AgCl (CH Instruments, Bee 
Cave, TX) was used as the reference electrode. Measured potentials were calibrated vs. 
RHE after experiments were conducted (to prevent platinum contamination) by measuring 
the potential difference between a pristine platinum electrode (Standard Platinum Counter 
Electrode, Pine Research) and the reference electrode in H2-saturated H2SO4. High-purity 
H2 and N2 were used throughout these experiments (Welders Supply, Louisville, KY).  
 A Metrohm Autolab PGSTAT302N potentiostat/galvanostat, operating in 
potentiostat mode, was used to obtain polarization and frequency response analysis (FRA) 
data. Reductive cycling to activate the catalyst and evaluate its stability was carried out 
between 0 V and –0.8 V vs. RHE at 50 mV/sec. Linear sweep voltammetry was carried out 
intermittently throughout the cycling process, from 0 V to –0.8 V vs. RHE at 2 mV/sec, to 
evaluate the activity of the catalyst, at a relatively high resolution, after various amounts of 
usage at reductive potentials. FRA data was collected with an applied DC bias of –0.3 V 
vs. RHE, starting at 100 kHz and finishing at 0.02 Hz, with 5 mVRMS amplitude. The 
working electrode was rotated at 800 RPM throughout electrochemical characterization to 
assist the diffusion of H2 gas away from the catalyst surface. Measured values were iR-
compensated by multiplying the measured current at each point by the real component of 
resistance measured at 100 kHz and then subtracting these values from the corresponding 
applied potentials. 
2.3 Synthetic Procedures  
All reagents and solvents were purchased from commercial sources and used as 
received unless otherwise indicated. Reactions were conducted open to air and under 
ambient conditions unless otherwise noted. Solvents ethanol and methanol were grades 
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absolute and 99.8%, respectively. Xanthates,79 hydrazinecarbothioic acid O-alkyl esters80, 
mono-keto-thiosemicarbazones,18,81 H2ATSM, H2ATSDM, H2ATSM-F6, 1, 2, and 3 were 
synthesized according to literature methods.8,32  
N,N′-bis(methylthiocarbamate)butane-2,3-diimine (4). The hydrazinecarbothioic acid 
O-methyl ester (3.2 g, 30 mmol) was dissolved in ethanol (50 mL). To this solution 2,3-
butanedione (1.3 mL, 15 mmol) was added by syringe with stirring. A catalytic amount (5 
drops) of concentrated sulfuric acid was added resulting in a white precipitate. The 
suspension was stirred for 16 h. The white precipitate was isolated by filtration and washed 
with ethanol and ether. Yield = 3.6 g (93%). 1H NMR, (C2D6SO, 400 MHz) δ 2.11 (s, 6H) 
4.03 (s, 6H) 11.46 (s, 1H) 11.77 (s, 1H). 13C {1H} NMR, (CDCl3, 100 MHz) δ 12.3, 58.5, 
117.8, 188.0. IR, cm-1: 3240 (w) and 1503 (m) (NH) 1419 (m) (CH) 1341 (m) and 1222 (s) 
(CN) 1137 (s) (CO) 1060 (s) (CS). 
N,N′-bis(ethylthiocarbamate)butane-2,3-diimine (5). Compound 5 was prepared using 
the same protocol as for 4. Addition of 2,3-butanedione (2.3 mL, 27 mmol) to 
hydrazinecarbothioic acid O-ethyl ester (6.4 g, 53 mmol) in ethanol (50 mL) yielded 2 as 
a white solid. Yield = 7.74 g (98%). 1H NMR, (C3D7NO, 400 MHz) δ 1.51 (br, 6H) 2.46 
(br, 4H) 4.74 (s, 6H) 11.51 (s, 1H) 11.92 (s, 1H). IR, cm-1: 3241 (w) and 1498 (s) (NH) 
1403 (m) (CH) 1317 (m) and 1211 (s) (CN) 1135 (m) (CO) 1049 (m) (CS).  
N,N′-bis(n-propylthiocarbamate)butane-2,3-diimine (6). Compound 6 was prepared as 
described for 4 from hydrazinecarbothioic acid O-propyl ester (2.1 g, 15 mmol) and 2,3-
butanedione (0.66 mL, 7.5 mmol) in ethanol (50 mL). Yield = 0.95 g (40%). 1H NMR, 
(CDCl3, 400 MHz) δ 0.99 (t, 6H, J=7.28 Hz) 1.84 (quint, 4H, J = 6.24 Hz) 2.13 (s, 6H) 
4.55 (t, 4H, J = 6.22 Hz) 9.15 (s, 2H). 13C{1H} NMR, (CDCl3, 100 MHz) δ 9.78, 10.3, 
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21.9, 29.7, 187.6. IR, cm-1: 3234 (w) and 1497(s) (NH) 1402 (m) (CH) 1334 (m) and 1207 
(s) (CN) 1135 (s) (CO) 1052 (s) (CS). 
N,N′-bis(isopropylthiocarbamate)butane-2,3-diimine (7). Compound 7 was prepared as 
described for 4 from hydrazinecarbothioic acid O-isopropyl ester (5.1 g, 38 mmol) and 2,3-
butanedione (1.7 mL, 19 mmol) in ethanol (50 mL). Yield = 1.4 g (23%). 1H NMR, (CDCl3, 
400 MHz) δ 1.41 (br, 12H) 2.12 (s, 6H) 5.63 (br, 2H) 9.10 (s, 2H). 13C{1H} NMR, (CDCl3, 
100 MHz) δ 10.3, 21.9. IR, cm-1: 3234 (w) and 1497(s) (NH) 1402 (m) (CH) 1334 (m) and 
1207 (s) (CN) 1135 (s) (CO) 1052 (s) (CS). 
N,N′-bis(octylthiocarbamate)butane-2,3-diimine (8). Compound 8 was prepared as 
described for 4 from hydrazinecarbothioic acid O-octyl ester (2.72 g, 13 mmol) and 2,3-
butanedione (0.58 mL, 6.7 mmol) in ethanol (50 mL,). Yield = 1.77 g (58%). 1H NMR, 
(CDCl3, 400 MHz) δ 0.87 (br, 6H) 1.28 (m, 16H) 1.43 (br, 4H) 1.81 (br, 4H) 2.13 (s, 6H) 
4.59 (br, 4H) 9.12 (s, 2H). 13C{1H} NMR, (CDCl3, 100 MHz) δ 14.1, 22.6, 25.8, 28.4, 29.1, 
31.7. IR, cm-1: 3230 (w) and 1497 (vs) (NH) 2950-2850 (m) and 1404 (s) (CH) 1326 (s) 
and 1206 (vs) (CN) 1136 (s) (CO) 1056 (s) (CS). 
N,N′-bis(ethylthiocarbamate)hexane-3,4-diimine (9). Compound 9 was prepared as 
described for 4 from hydrazinecarbothioic acid O-ethyl ester (1.53 g, 13 mmol) and 3,4-
hexanedione (0.77 mL, 6.5 mmol) in ethanol (50 mL). Yield = 1.2 g (60%). 1H NMR, 
(CDCl3, 400 MHz) δ 1.08 (br, 6H) 1.41 (br, 6H) 2.63 (br, 4H) 4.63 (br, 4H) 9.23 (br, 2H). 
13C{1H} NMR, (CDCl3, 100 MHz) δ 10.49, 14.02, 17.01, 68.87, 152.27, 187.47. IR, cm
-1: 
3235 (w) and 1498 (m) (NH) 1433 (w) (CH) 1314 (m) and 1206 (s) (CN) 1152 (m) (CO) 
1059 (s) (CS). 
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Cu(MTCB) (10). Compound 4 (0.273 g, 1.29 mmol) was suspended in methanol (25 mL, 
100%). To this suspension copper(II) acetate monohydrate (0.285 g, 1.49 mmol) was added 
with stirring giving a red-brown precipitate. The suspension was refluxed with stirring for 
4 h and then allowed to cool to room temperature. The formed solid was filtered, washed 
with methanol then ether and air dried. Yield = 0.216 g (52%). X-ray quality crystals were 
obtained by slow evaporation of a DCM solution of 10 layered with ethanol. IR, cm-1 : 
1471 (s) and 1398 (m) (CH) 1241 (vs) and 1218 (vs) (CN) 1091 (w) (CO) 948 (w) (CS) 
848 (w) (CuS) 771 (w) (CuN). UV-Visible spectrum in DCM, nm, (M-1 cm-1): 246 
(16,000), 290 (20,000), 486 (2,680). EPR g = 2.061. Elemental analysis calc. for 
C8H12S2O2N4Cu: C, 29.67, H, 3.73, N, 17.30, O, 9.88, S, 19.80. Found: C, 28.49, H, 3.58, 
N, 15.97, O, 8.54, S, 17.87. Mass spectrum calc. for C8H12S2O2N4Cu: 322.9698. Found: 
322.9775. 
Cu(ETCB) (11). Compound 11 was prepared using the method described for 10 from 5 
(0.309 g, 1.29 mmol) and copper(II) acetate monohydrate (0.285 g, 1.49 mmol) in methanol 
(25 mL). Complex 11 was isolated as a red-brown solid. Yield = 0.237 g (52%). X-ray 
quality crystals were obtained by using the technique described for 10. IR, cm-1: 1413 (s) 
(CH) 1216 (s) (CN) 1020 (m) (CO) 867 (w) (CS) 792 (w) (CuS) 673 (w) (CuN). UV-
Visible spectrum in DCM, nm, (M-1 cm-1): 248 (16,300), 290 (22,700), 485 (2920). EPR 
g|| = 2.131 and g = 2.036. Elemental analysis calc. for C10H16S2O2N4Cu: C, 34.13, H, 4.58, 
N, 15.92, O, 9.09, S, 18.22. Found: C, 34.08, H, 4.40, N, 15.46, O, 9.18, S, 18.22. Mass 
spectrum calc. for C10H16S2O2N4Cu: 351.0011. Found: 351.0086. 
Cu(PTCB) (12). Compound 12 was prepared using the method described for 10 from 6 
(0.408 g, 1.29 mmol) and copper(II) acetate monohydrate (0.285 g, 1.49 mmol) in methanol 
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(25 mL). Complex 12 was isolated as a red-brown solid. Yield = 0.322 g (68%). X-ray 
quality crystals were obtained by using the technique described for 10. IR, cm-1: 1467 (w) 
and 1423 (s) (CH) 1236 (s) (CN) 1093 (w) (CO) 956 (m) (CS) 844 (w) (CuS) 632 (w) 
(CuN). UV-Visible spectrum in DCM, nm, (M-1 cm-1): 248 (16,600), 291 (23,800), 484 
(2,930). EPR g|| = 2.127 and g = 2.034. Elemental analysis calc. for C12H20S2O2N4Cu: C, 
37.93, H, 5.31, N, 14.74, O, 8.42, S, 16.88. Found: C, 37.99, H, 5.10, N, 14.67, O, 8.32, S, 
16.75 Mass spectrum calc. for C12H20S2O2N4Cu: 379.0324. Found: 379.0417. 
Cu(iPTCB) (13). Compound 13 was prepared using the method described for 10 from 7 
(0.408 g, 1.29 mmol) and copper(II) acetate monohydrate (0.285 g, 1.49 mmol) in methanol 
(25 mL). Complex 13 was isolated as a red-brown solid. Yield = 0.291 g (60%). X-ray 
quality crystals were obtained by using the technique described for 10. IR, cm-1: 1427 (s) 
(CH) 1213 (vs) (CN) 1103 (vs) (CO) 910 (m) (CS) 831 (w) (CuS) 671 (w) (CuN). 
Elemental analysis calc. for C12H20S2O2N4Cu: C, 37.93, H, 5.31, N, 14.74, O, 8.42, S, 
16.88. Found: C, 37.38, H, 5.16, N, 14.39, O, 8.61, S, 17.10. UV-Visible spectrum in DCM, 
nm, (M-1 cm-1): 248 (16,500), 292 (23,600), 484 (3,210). EPR g|| = 2.089 and g = 2.042. 
Mass spectrum calc. for C12H20S2O2N4Cu: 379.0324. Found: 379.0401. 
Cu(OTCB) (14). Compound 14 was prepared using the method described for 10 from 8 
(0.589 g, 1.29 mmol) and copper(II) acetate monohydrate (0.285 g, 1.49 mmol) in methanol 
(25 mL). Complex 14 was isolated as a red-brown solid. Yield = 0.554 g (83%). X-ray 
quality crystals were obtained by using the technique described for 10. IR, cm-1: 2960-2852 
(m) and 1423 (s) (CH) 1238 (vs) (CN) 1079 (w) (CO) 946 (m) (CS) 846 (m) (CuS) 676 
(w) (CuN). UV-Visible spectrum in DCM, nm, (M-1 cm-1): 248 (15,900), 291 (23,600), 485 
(3,100). EPR g|| = 2.130 and g = 2.034.  Elemental analysis calc. for C22H40S2O2N4Cu: C, 
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50.79, H, 7.75, N, 10.77, O, 6.15, S, 12.33. Found: C, 50.49, H, 7.57, N, 10.65, O, 6.34, S, 
12.59. Mass spectrum calc. for C22H40S2O2N4Cu: 519.1889. Found: 519.1986. 
Cu(ETCH) (15). Compound 15 was prepared using the method described for 10 from 9 
(0.408, 1.29 mmol) and copper(II) acetate monohydrate (0.285 g, 1.49 mmol) in methanol 
(25 mL). Complex 15 was isolated as a red-brown solid. Yield = 0.401 g (82%). X-ray 
quality crystals were obtained by using the technique described for 7. IR, cm-1: 1417 (s) 
(CH) 1221 (s) (CN) 1016 (s) (CO) 974 (w) (CS) 874 (m) (CuS) 630 (m) (CuN). UV-Visible 
spectrum in DCM, nm, (M-1 cm-1): 249 (18,300), 292 (25,000), 485 (3,340). EPR g|| = 2.124 
and g = 2.031.  Elemental analysis calc. for C12H20S2O2N4Cu: C, 37.93, H, 5.31, N, 14.74, 
O, 8.42, S, 16.88. Found: C, 37.71, H, 4.96, N, 14.43, O, 8.33, S, 16.95. Mass spectrum 
calc. for C12H20S2O2N4Cu: 379.0324. Found: 379.0315. 
H2MEB (16). Diacetyl-2-(4-N-methyl-3-thiosemicarbazone) (0.894 g, 6.3 mmol) was 
suspended in ethanol (25 mL), and hydrazinecarbothioic acid O-ethyl ester (0.760 g, 6.3 
mmol) was added. A catalytic amount (6 drops) of concentrated sulfuric acid was added 
resulting in a white precipitate. The solid was isolated by filtration and washed with water 
then ethanol. Yield = 1.32 g (76%). 1H NMR, (C2D6SO, 400 MHz), δ 1.28 (br, 3H), 2.11 
and 2.17 (br, 6H), 3.00 (s, 3H), 8.35 (s, 1H), 10.21 (s, 1H) 11.31 and 11.62 (s, 1H). 13C 
NMR, (C2D6SO, 100 MHz) δ 11.8, 12.5, 31.7, 66.3, 67.5, 147.9, 152.5, 179.0, 187.0. IR, 
cm-1: 3382, 3253, 1541, 1494 (NH), 2991 and 1411 (CH), 1304 and 1217 (CN), 1130 (CO), 
1053 (CS). Elemental analysis calc. for C9H17S2ON5: C, 39.25, H, 6.22, N, 25.43. Found: 
C, 39.12, H, 6.16, N, 25.54. 
H2MPB (17). Compound 17 was prepared using the method for 16. Addition of 
hydrazinecarbothioic acid O-propyl ester (0.1.45 g, 11 mmol) to diacetyl-2-(4-N-methyl-
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3-thiosemicarbazone) (1.58 g, 11 mmol) in ethanol (25 mL) yielding a white solid. Yield 
= 1.32 g (75%). 1H NMR, (C2D6SO, 400 MHz), δ 0.94 (br, 3H) 1.70 (br, 2H), 2.11 and 
2.19 (s/br, 6H) 3.00 (s, 3H) 4.41 (br, 2H) 8.43 (s, 1H) 10.25 (s, 1H) 11.35 and 11.63 (s, 
1H). 13C NMR, (C2D6SO, 100 MHz), δ 10.8, 22.0, 31.7, 179.0. IR, cm
-1: 3382, 3231, 1540, 
1497 (NH), 2968 and 1411 (CH), 1303 and 1211 (CN), 1132 (CO), 1068 (CS). Elemental 
analysis calc. for C10H19S2ON5: C, 41.50, H, 6.62, N, 24.20. Found: C, 41.31, H, 6.46, N, 
24.02. 
H2MEP (18). Compound 18 was prepared from using the method described for 16. 
Addition of hydrazinecarbothioic acid O-ethyl ester (0.43 g, 3.6 mmol) to 1-phenyl-2-
propanone-1-(4-N-methyl-3-thiosemicarbazone) (0.840 g, 3.6 mmol) in ethanol (25 mL) 
yielding a white solid. Yield = 0.871 g (72%). IR, cm-1: 3336, 3223, 1476, 1542 (NH), 
2937 and 1417 (CH), 1301 and 1219 (CN), 1195 (CO), 1081 (CS). Elemental analysis calc. 
for C14H19S2ON5: C, 49.83, H, 5.67, N, 20.75. Found: C, 49.14, H, 5.60, N, 20.18. 
Cu(MEB) (19). Compound 16 (0.354 g, 1.29 mmol) was suspended in methanol (25 mL, 
100%). To this suspension copper(II) acetate monohydrate (0.285 g, 1.49 mmol) was added 
with stirring giving a red-brown precipitate. The suspension was refluxed with stirring for 
4 h and then cooled to room temperature. The solid was then filtered and washed with 
methanol. Yield = 0.220 g (51%). IR, cm-1: 3305 and 1561 (NH), 2937 and 1439 (CH), 
1382 and 1217 (CN), 1132 (CO), 1025 (CS), 846 (CuS) 782 (CuN). UV-Visible spectrum 
in DCM, nm, (M-1 cm-1): 248 (16,000), 309 (20,000), shoulder around 346 (11,000), 473 
(5,100).  EPR g = 2.061. Elemental analysis calc. for C9H15S2ON5Cu: C, 32.08, H, 4.49, 
N, 20.79. Found: C, 31.53, H, 4.34, N, 20.26 Mass spectrum calc. for C9H15S2ON5Cu: 
336.00141. Found: 337.0080. 
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Cu(MPB) (20). Compound 20 was prepared using the same method as described for 19 
from 17 (0.373 g, 1.29 mmol) and copper(II) acetate monohydrate (0.285 g, 1.49 mmol) in 
methanol (25 mL). Compound 20 was isolated as a red-brown solid. Yield = 0.200 g (44%). 
IR, cm-1: 3329 and 1562 (NH), 2972 and 1465 (CH), 1382 and 1219 (CN), 1019 (CO), 974 
(CS), 872 (CuS), 758 (CuN). UV-Visible spectrum in DCM, nm, (M-1 cm-1): 249 (13,000), 
310 (17,000), shoulder around 346 (8,700), 477 (4,300). EPR g|| = 2.116 and g = 2.030. 
Elemental analysis calc. for C10H17S2ON5Cu: C, 34.22, H, 4.88, N, 19.96. Found: C, 34.17, 
H, 4.83, N, 20.01. Mass spectrum calc. for C10H17S2ON5Cu: 350.01706. Found: 351.0239. 
Cu(MEP) (21). Compound 21 was prepared using the same method as described for 19 
from 18 (0.435 g, 1.29 mmol) and copper(II) acetate monohydrate (0.285 g, 1.49 mmol) in 
methanol (25 mL). Compound 21 was isolated as a red-brown solid. Yield = 0.146 g (29%). 
IR cm-1. 3324 and 1538 (NH), 2973 and 1428 (CH), 1382 and 1219 (CN), 1019 (CO), 974 
(CS), 872 (CuS) 758 (CuN). UV-Visible spectrum in DCM, nm, (M-1 cm-1): Shoulder 
around 263 (16,000), 309 (20,000), shoulder around 357 (13,000), 485 (5,500). EPR g|| = 
2.135 and g = 2.032. Elemental analysis calc. for C14H17S2ON5Cu: C, 42.14, H, 4.29, N, 
17.55. Found: C, 41.84, H, 4.22, N, 17.53. Mass spectrum calc. for C14H17S2ON5Cu: 
398.01706. Found: 339.0238. 
Ni(MEB) (22). Compound 16 (0.354 g, 1.29 mmol) was suspended in methanol (25 mL). 
To this suspension nickel(II) acetate tetrahydrate (0.353 g, 1.49 mmol) was added with 
stirring giving a dark brown precipitate. The suspension was refluxed for 4 h and then 
cooled to room temperature prior to being placed in a freezer overnight. The formed solid 
was filtered cold then washed with methanol. Yield = 0.326 g (76%). 1H NMR, (C2D6SO, 
400 MHz), δ 1.21 (t, 3H) 2.00 (s, 6H) 2.81(s, 3H) 4.20 (br, 2H) 8.03 (s, 1H). IR, cm-1: 3414 
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and 1553 (NH), 2937 and 1402 (CH), 1382 and 1216 (CN), 1080 (CO), 1014 (CS), 872 
(NiS), 782 (NiN). UV-Visible spectrum in DCM, nm, (M-1 cm-1): 255 (38,000), shoulder 
around 326 (6,400), 389 (12,000). Elemental analysis calc. for C9H15S2ON5Ni: C, 32.55, 
H, 4.55, N, 21.09. Found: C, 32.09, H, 4.44, N, 20.54. Mass spectrum calc. for 
C9H15S2ON5Ni: 331.00716. Found: 331.0062 and 332.0140. 
Ni(MPB) (23). Compound 23 was prepared using the method described for 22 from 17 
(0.373 g, 1.29 mmol) and nickel(II) acetate tetrahydrate (0.353 g, 1.49 mmol) in methanol 
(25 mL). Compound 23 was isolated as a dark brown solid. Yield = 0.250 g (56%). 1H 
NMR, (C2D6SO, 400 MHz) δ 0.87 (t, 3H) 1.59 (br, 2H) 2.01 (br, 6H) 2.81 (s, 3H) 4.12 (br, 
2H) 8.02 (s, 1H). IR, cm-1: 3341 and 1562 (NH), 29333 and 1493 (CH), 1307 and 1225 
(CN), 1084 (CO), 1042 (CS), 855 (NiS) 735 (NiN). UV-Visible spectrum in DCM, nm, 
(M-1 cm-1): 255 (32,000), shoulder around 330 (4,500), 388 (11,000). Elemental analysis 
calc. for C10H17S2ON5Ni: C, 34.70, H, 4.95, N, 20.24. Found: C, 34.49, H, 4.86, N, 19.92. 
Mass spectrum calc. for C10H17S2ON5Ni: 345.02281. Found: 345.0128 and 346.0296. 
Ni(MEP) (24). Compound 24 was prepared using the method described for 22 from 18 
(0.435 g, 1.29 mmol) and nickel(II) acetate tetrahydrate (0.353 g, 1.49 mmol) in methanol 
(25 mL). Compound 24 was isolated as a dark brown solid. Yield = 0.332 g (65%). 1H 
NMR, (C2D6SO, 400 MHz) δ 1.12 (t, 3H) 1.80 (s, 3H) 2.85 (s, 3H) 7.46 (br, 5H) 8.19 (s, 
1H). IR, cm-1: 3408, 3256, and 1544 (NH), 2975 and 1500 (CH), 1332 and 1226 (CN), 
1016 (CO), 975 (CS), 874 (NiS) 758 (NiN). UV-Visible spectrum in DCM, nm, (M-1 cm-
1): 252 (30,000), 342 (7,600), 405 (11,000).  Elemental analysis calc. for C14H17S2ON5Ni: 
C, 42.66, H, 4.35, N, 17.77. Found: C, 42.85, H, 4.46, N, 17.57. Mass spectrum calc. for 
C14H17S2ON5Ni: 393.02281. Found: 393.0214 and 394.0295. 
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Zn(MEB) (25). Compound 16 (0.354 g, 1.29 mmol) was suspended in methanol (25 mL). 
To this suspension zinc(II) acetate dihydrate (0.307 g, 1.49 mmol) was added with stirring 
giving a yellow-orange precipitate. The suspension was refluxed for 4 h and then cooled to 
room temperature. The formed solid was filtered and then washed with methanol. Yield = 
0.275 g (63%). 1H NMR, (C2D6SO, 400 MHz), δ 1.26 (t, 3H) 2.22 (s, 3H) 2.25 (s, 3H) 2.84 
(3H) 4.30 (br, 2H) 7.48 (1H). 13C NMR, (C2D6SO, 100 MHz) δ 14.2, 14.9, 64.0, 110.0. IR, 
cm-1: 3337 and 1557 (NH), 2930 and 1494 (CH), 1397 and 1227 (CN), 1082 (CO), 1027 
(CS), 841 (ZnS), 774 (ZnN). UV-Visible spectrum in DCM, nm, (M-1 cm-1): 243 (12,000), 
299 (9,900), 422 (8,700). Elemental analysis calc. for C9H15S2ON5Zn: C, 31.91, H, 4.46, 
N, 20.67. Found: C, 31.92, H, 4.45, N, 20.67. Mass spectrum calc. for 
C9H15S2ON5Zn: 337.00096. Found: 338.2153. 
Zn(MPB) (26). Compound 26 was prepared using the same method as described for 25 
from 17 (0.373 g, 1.29 mmol) and zinc(II) acetate dihydrate (0.307 g, 1.49 mmol) in 
methanol (25 mL). Compound 26 was isolated as a yellow-orange precipitate. Yield = 
0.424 g (93%). 1H NMR, (C2D6SO, 400 MHz), δ 0.92 (t, 3H) 1.66 (br, 2H) 2.20 (s, 3H) 
2.22 (s, 3H) 2.85 (s, 3H) 4.21 (br, 2H) 7.48 (s, 1H). 13C NMR, (C2D6SO, 100 MHz), δ 10.9, 
14.9, 22.3, 69.7, 110.0. IR, cm-1: 3367, 3311, and 1549 (NH), 2973 and 1491 (CH), 1372 
and 1209 (CN), 1122 (CO), 1079 (CS), 836 (ZnS), 783 (ZnN). UV-Visible spectrum in 
DCM, nm, (M-1 cm-1): 243 (10,000), 299 (7,400), 423 (7,500). Elemental analysis calc. for 
C10H17S2ON5Zn·CH3OH: C, 34.33, H, 5.50, N, 18.20. Found: C, 33.99, H, 5.25, N, 18.12. 
Mass spectrum calc. for C10H17S2ON5Zn: 351.0166. Found: 352.07. 
Zn(MEP) (27). Compound 27 was prepared using the same method as described for 25 
from 18 (0.435 g, 1.29 mmol) and zinc(II) acetate dihydrate (0.307 g, 1.49 mmol) in 
  
34 
  
methanol (25 mL). Compound 27 was isolated as a yellow-orange precipitate. Yield = 
0.322 g (62%). 1H NMR, (C2D6SO, 400MHz), δ 1.14 (t, 3H) 2.03 (s, 3H) 2.87 (s, 3H) 4.08 
(br, 2H) 7.45 (br, 5H) 7.61 (s, 1H). 13C NMR, (C2D6SO, 100MHz), δ 14.8, 16.2, 110.0, 
128.4, 129.5, 129.7, 132.9. IR, cm-1: 3351 and 1541 (NH), 2971 and 1481 (CH), 1392 and 
1221 (CN), 1019 (CO), 970 (CS), 801 (ZnS), 756 (ZnN). UV-Visible spectrum in DCM, 
nm, (M-1 cm-1): 269 (11,000), 326 (8,100), 430 (7,300). Elemental analysis calc. for 
C14H17S2ON5Zn: C, 41.95, H, 4.27, N, 17.47. Found: C, 40.65, H, 4.08, N, 19.97. Mass 
spectrum calc. for C14H17S2ON5Zn: 399.01661. Found: 400.3753. 
Ni(ATSDM) (28). The ligand H2ATSDM (0.28 g, 0.96 mmol) was suspended in methanol 
(25 mL). To this suspension, nickel (II) acetate tetrahydrate (0.25 g, 1.0 mmol) was added 
with stirring giving a dark green-brown precipitate. The suspension was refluxed for 4 h 
and then cooled to room temperature prior to being placed in a freezer overnight. The 
formed solid was filtered cold and washed with water then ethanol giving a red-brown 
solid. Yield = 0.293 g (88%). X-ray quality crystals were obtained by dissolving 
Ni(ATSDM) in acetonitrile, which was then layered with ether and allowed to slowly 
evaporate. 1H NMR, (C2D6SO, 400 MHz) δ 1.87 (s, 3H) 3.10 (s, 6H). IR, cm
-1: 2910 (w) 
and 1501 (s) (CH) 1366 (vs) and 1082 (m) (C-N) 1322 (vs) and 1258 (s) (C=N) 1006 (w) 
(CS) 900 (m) (NiS) 783 (w) (NiN). UV-Visible spectrum in acetonitrile, nm, (M-1 cm-1): 
256(23,000), 411 (11,000), 436 (11,000). Elemental analysis calc. for C10H18N6S2Ni: C, 
34.80, H, 5.26, N, 24.35. Found: C, 34.57, H, 5.20, N, 24.12. Mass spectrum calc. for 
C10H18N6S2Ni: 344.03878 Found: 343.80 and 344.80.  
Ni(ATSM-F6) (29). The ligand H2ATSM-F6 (0.19 g, 0.48 mmol) was suspended in 
methanol (20 mL). To this suspension, nickel(II) acetate tetrahydrate (0.15 g, 0.60 mmol) 
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was added with stirring, giving a red-brown precipitate. The suspension was refluxed for 4 
h and then cooled to room temperature prior to being placed in a freezer overnight. The 
formed solid was filtered cold and washed with water then ethanol giving a red-brown 
solid. Yield = 0.087 g (40%). X-ray quality crystals were obtained by dissolving 
Ni(ATSM-F6) in acetonitrile, which was then layered with ether and allowed to slowly 
evaporate. 1H NMR, (C2D6SO, 400 MHz), δ 1.94 (s, 3H) 4.00 (br, 2H) 8.29 (s, 1H). 
13C 
NMR, (C2D6SO, 100 MHz), δ 178.1, 158.8, 124.9 (q, J = 280 Hz), 46.3 (q, J = 33 Hz) 14.4. 
IR cm-1: 3462 (m) (NH) 1514 (s) and 1476 (s) (CH) 1271 (s) and 1218 (m) (CN) 1138 (vs) 
(CF) 941 (w) (NiS) 832 (w) (NiN). UV-Visible spectrum in acetonitrile, nm, (M-1 cm-1): 
259 (24,000), 328 (8,200), 392 (9,100). Elemental analysis calc. for C10H12N6S2F6Ni: C, 
26.51, H, 2.67, N, 18.55, F, 25.16. Found: C, 26.36, H, 2.59, N, 18.29, F, 25.10. Mass 
spectrum calc. for C10H18N6S2Ni: 451.98223 Found: 452.87.  
2.4 Crystallographic Studies  
 Single crystal X-ray diffraction studies were conducted on complexes 10-15, 18, 
19, 21, 22, 28, and 29. The CCDC deposit numbers and references can be found in Table 
2-1. Suitable crystals for X-ray diffraction of 10-15, 18, 19, 21, and 22 were grown from a 
sealed tube in which dichloromethane was layered with ethanol. For 28 and 29, crystals 
were grown from a sealed tube in which acetonitrile was layered with diethyl ether. 
Table 2-1. CCDC and publication reference information 
Compound CCDC number Reference  
10 1517907 82 
11 1517908 82 
12 1517909 82 
13 1517910 82 
14 1517911 82 
15 1517912 82 
18 N/A 83 
19 N/A 83 
21 N/A 83 
22 N/A 83 
28 1866543 84 
29 1866544 84 
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 Crystals 10, 11, and 29 were mounted on a CryoLoop and 12 – 15 and 28 were 
mounted on a glass fiber for collection of X-ray data on an Agilent Technologies/Oxford 
Diffraction Gemini CCD diffractometer. The CrysAlisPro85 CCD software package (v 
1.171.36.32) was used to acquire -scan exposures of data at 100K using monochromated 
MoKα radiation (0.71073 Å) from a sealed tube. Frame data were processed using 
CrysAlisPro85 RED to determine final unit cell parameters to produce raw hkl data that 
were then corrected for absorption using SCALE3 ABSPACK.86 The structures of 10–15 
were solved by Direct Methods using SHELX87 and refined by least squares methods on 
F2 using SHELXL-97.87 Crystals 28 and 29 were solved by Direct Methods using 
SHELXS87 and refined by least squares methods on F2 using SHELXL87 For all crystals 
non-hydrogen atoms were refined anisotropically.  
 For crystals 11–15 and 28, all hydrogens atoms were located by difference maps 
and refined isotropically. For 10 and 29 methyl hydrogen atoms were placed in their 
geometrically generated positions and refined as a riding model and these atoms were 
assigned U(H) = 1.5 x Ueq. The imine NH hydrogen atoms of 29 were located by difference 
maps and refined isotropically. For all unique reflections the final anisotropic full matrix 
least-squares refinement on F2 for all variables converged with R1, wR2, GOF as listed in 
the Tables 2-2 to 2-4.  
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Table 2-2. Crystal data and structural refinement for 10-13 
Compound 10 11 12 13 
Empirical formula C8H12CuN4O2S2 C10H16CuN4O2S2 C12H20CuN4O2S2 C12H20CuN4O2S2 
Formula weight 323.89 351.93 379.98 379.98 
Temperature (K) 99.95(10)   100.05(10) 99.95(10) 99.95(10)      
Wavelength (Å) 0.71073 0.71073 0.71073 0.71073 
Crystal system Orthorhombic Triclinic Orthorhombic Monoclinic 
Space group Pbcn P-1 Pbcn P21/c 
Unit cell dimension 
a (Å) 
b (Å) 
c (Å) 
α (°) 
β (°) 
γ (°) 
16.8510(16) 
8.8146(7) 
8.2090(8) 
90 
90 
90 
8.5267(4) 
8.7430(3) 
10.4065(4) 
80.502(3) 
72.838(4) 
70.532(4) 
22.6633(9) 
9.0529(3) 
7.8296(2) 
90 
90 
90 
14.6103(8) 
16.3511(6) 
7.0344(8) 
90 
98.413(5) 
90 
Volume (Å3) 1219.3(2) 696.95(5) 1606.38(10) 1662.40(14) 
Z 4 2 4 4 
ρcalcd. (Mg/m3) 1.764 1.677  1.571 1.518 
Abs. coeff. (mm-1) 2.128  1.869  1.628  1.573 
F(000) 660 362 788 788 
Crystal colour, habit Thin orange plate Dark purple plate Orange plate Orange plate 
Crystal size (mm3) 0.18 x 0.18 x 0.03 0.17 x 0.08 x 0.03  0.28 x 0.07 x 0.03 0.33 x 0.10 x 0.02 
θ range data collection (°) 3.60 to 25.35 3.33 to 27.14° 3.51 to 27.09° 3.30 to 26.10° 
Index ranges -20 ≤ h ≤ 19 
-10 ≤ k ≤ 9 
-9 ≤ 1 ≤ 9 
-10 ≤ h ≤ 10 
-11 ≤ k ≤ 11 
-13 ≤ 1 ≤ 13 
-29 ≤ h ≤ 26 
-11 ≤ k ≤ 10 
-10 ≤ 1 ≤ 10 
-18 ≤ h ≤ 18 
-20 ≤ k ≤ 20 
-8 ≤ 1 ≤ 8 
Reflections collected 6029 15161 9630 13215 
Independent reflections 1119 
[R(int) = 0.0503] 
3074 
[R(int) = 0.0257] 
1772 
[R(int) = 0.0337] 
3292 
[R(int) = 0.050] 
Completeness to θ max  99.8%  99.8% 99.8%  99.5%  
Absorption correction Multi-scan Multi-scan Multi-scan Multi-scan 
Max. and min. trans. 1.000 and 0.517 1.000 and 0.865 1.000 and 0.864 1.000 and 0.656 
Refinement method Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Data/restraints/params 1119 / 0 / 80 3074 / 0 / 236 1772 / 0 / 136 3292 / 0 / 270 
Goodness-of-fit on F2 1.072 1.049 1.034 1.043 
Final R indices 
[I>2σ(I)]a,b 
R1 = 0.0523 
wR2 = 0.0723 
R1 = 0.0206 
wR2 = 0.0519 
R1 = 0.0259 
wR2 = 0.0637 
R1 = 0.039 
wR2 = 0.079 
R indices (all data) R1 = 0.0867 
wR2 = 0.0792 
R1 = 0.0229 
wR2 = 0.0532 
R1 = 0.0327 
wR2 = 0.0672 
R1 = 0.054 
wR2 = 0.086 
Largest difference peak 
and hole (e·Å3) 
0.465 and -0.537 0.499 and -0.347 0.440 and -0.275 0.647 and -0.559 
aR1 = Σ||Fo| - |Fc||/Σ|Fo|; b wR2 = {Σ[w(Fo2– Fc2) 2]/Σ[w(Fo2) 2]}1/2; where w = q/σ2(Fo2) + (qp) 2 + bp. GOF = 
S = {Σ[w(Fo2– Fc2) 2]/(n – p)}1/2, where n is the number of reflections and p is the number of parameters 
refined. 
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Table 2-3. Crystal data and structural refinement for 14, 15, 18, and 19 
Compound 14 15 18 19 
Empirical formula C22H40CuN4O2S2 C12H20CuN4O2S2 C14H19N5OS2 C18H30Cu2N10O2S4 
Formula weight 520.24 379.98 337.46 673.84 
Temperature (K) 99.95(10) 99.95(10) 102.0(3) 100.1(9) 
Wavelength (Å) 0.71073 0.71073 0.71073 0.71073 
Crystal system Orthorhombic Monoclinic Monoclinic Triclinic 
Space group Pbcn C2/c P21/c P-1 
Unit cell dimension 
a (Å) 
b (Å) 
c (Å) 
α (°) 
β (°) 
γ (°) 
30.6050(7) 
9.10885(20) 
9.19230(19) 
90 
90 
90 
20.267(2) 
9.1509(9) 
9.0767(10) 
90 
102.350(12) 
90 
9.91024(14) 
16.6144(2) 
20.7808(3) 
90 
96.2668(13) 
90 
8.2759(4) 
10.2427(3) 
16.8758(6) 
74.102(3) 
89.740(4) 
85.364(3) 
Volume (Å3) 2526.60(9) 1644.4(3) 3401.16(8) 1371.07(9) 
Z 4 4 8 2 
ρcalcd. (Mg/m3) 1.348 1.535 1.318 1.632 
Abs. coeff. (mm-1) 1.040 1.590 0.322 1.893 
F(000) 1108 788 1424 692 
Crystal colour, habit Orange needle Orange plate Yellow prism Dark orange needle 
Crystal size (mm3) 0.37 x 0.07 x 0.04 0.49 x 0.07 x 0.01 0.40 x 0.35 x 0.33 0.31 x 0.05 x 0.05 
θ range data collection 
(°) 
3.42 to 27.14° 3.21 to 28.16° 3.21 to 30.55 3.36 to 28.16 
Index ranges -39 ≤ h ≤ 39 
-11 ≤ k ≤ 11 
-11 ≤ 1 ≤ 11 
-26 ≤ h ≤ 26 
-12 ≤ k ≤ 12 
-11 ≤ 1 ≤ 12 
-14 ≤ h ≤14  
-23 ≤ k ≤23 
-29 ≤ l ≤29 
-10 ≤ h ≤10  
-13 ≤ k ≤13 
-22 ≤ l ≤22 
Reflections collected 35054 10256 81797 25443 
Independent 
reflections 
2836 
[R(int) = 0.0382] 
2003 
[R(int) = 0.0702] 
10411  
[R(int) = 0.0416] 
6693 
[R(int) = 0.0306] 
Completeness to θ 
max  
99.8%  99.6%  99.9% 99.6% 
Absorption correction Multi-scan Multi-scan Multi-scan Semi-empirical from 
equivalents 
Max. and min. trans. 1.000 and 0.871 1.000 and 0.577 1.000 and 0.970 1.000 and 0.673 
Refinement method Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Data/restraints/params 2836 / 0 / 221 2003 / 0 / 136 10411 / 0 / 483 6693 /0 / 445 
Goodness-of-fit on F2 1.013 1.085 1.036 1.039 
Final R indices 
[I>2σ(I)]a,b 
R1 = 0.0244 
wR2 = 0.0618 
R1 = 0.0398 
wR2 = 0.0937 
R1 = 0.387, 
wR2 = 0.0825 
R1 = 0.0385, 
wR2 = 0.0767 
R indices (all data) R1 = 0.0295 
wR2 = 0.0649 
R1 = 0.0562 
wR2 = 0.1059 
R1 = 0.0500, 
wR2 = 0.0878 
R1 = 0.0486, 
wR2 = 0.0821 
Largest difference 
peak and hole (e·Å3) 
0.359 and -0.206 0.874 and -0.492 0.447 and -0.377 1.653 and -0.923 
aR1 = Σ||Fo| - |Fc||/Σ|Fo|; b wR2 = {Σ[w(Fo2– Fc2) 2]/Σ[w(Fo2) 2]}1/2; where w = q/σ2(Fo2) + (qp) 2 + bp. GOF = 
S = {Σ[w(Fo2– Fc2) 2]/(n – p)}1/2, where n is the number of reflections and p is the number of parameters 
refined.  
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Table 2-4. Crystal data and structural refinement for 21, 22, 28, and 29 
Compound 21 22 28 29 
Empirical formula C28H34Cu2N10O2S4 C9H15N5NiOS2 C10H18N6NiS2 C10H12F6N6NiS2 
Formula weight 797.97 332.09 345.13 453.09 
Temperature (K) 100.2(6) 102(3) 100.2(6) 100(2) 
Wavelength (Å) 0.71073 0.71073 0.71073 0.71073 
Crystal system Triclinic Monoclinic Triclinic Triclinic 
Space group P-1 P21/c P-1 P-1 
Unit cell dimension 
a (Å) 
b (Å) 
c (Å) 
α (°) 
β (°) 
γ (°) 
10.2767(5) 
11.8398(5) 
14.8880(6) 
73.776(4) 
78.850(4) 
75.204(4) 
7.7351(2) 
20.8045(6) 
8.2308(3) 
90 
93.119(3) 
90 
7.33437(16) 
8.5595(2) 
11.6784 
103.865(2) 
98.2102(19) 
91.7205(18) 
8.3598(10) 
9.4027(10) 
13.5112(17) 
109.467  
105.475(11) 
91.382(9)  
Volume (Å3) 1667.09(13) 1322.58(7) 702.92(3) 957.53(19) 
Z 2 4 2 2 
calcd.. (Mg/m3) 1.590 1.668 1.631 1.571 
Abs. coeff. (mm-1) 1.571 1.778 1.672 1.291 
F(000) 820 688 360 456 
Crystal colour, habit Orange plate Thin orange plate Orange prsim Red-brown plate 
Crystal size (mm3) 0.31 x 0.17 x 0.03 0.38 x 0.05 x 0.01 0.40 x 0.34 x 0.18 0.41 x 0.08 x 0.01 
θ range data collection 
(°) 
3.31 to 29.21 3.65 to 26.06 3.40 to 31.57 3.30 to 26.67 
Index ranges -14 ≤ h ≤14  
-16 ≤ k ≤16 
-20 ≤ l ≤20 
-9 ≤ h ≤9  
-25 ≤ k ≤24 
-10 ≤ l ≤10 
-10≤ h ≤ 10 
-12 ≤ k ≤12 
-17 ≤ l ≤ 17 
-10≤ h ≤ 10 
-11 ≤ k ≤11 
-17 ≤ l ≤ 17 
Reflections collected 44148 11760 19998 13904 
Independent 
reflections 
8974 
 [R(int) = 0.0373] 
2601  
[R(int) = 0.0316] 
4702 
 [R(int) = 0.0217] 
4031  
[R(int) = 0.058] 
Completeness to θ 
max 
99.2% 99.4% 99.9 % 99.7% 
Absorption correction Semi-empirical 
from equivalents 
Multi-scan Multiscan Multiscan 
Max. and min. trans. 1.000 and 0.792 1.000 and 0.939 1.000 and 0.778 1.00 and 0.678 
Refinement method Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Data/restraints/params 8974/0/429 2601/1/179 4702/0/244 4031/0/288 
Goodness-of-fit- on F2 1.038 1.071 1.013 1.074 
Final R indices 
[I>2σ(I)]a,b 
R1= 0.028,  
wR2= 0.0618 
R1= 0.0353, 
wR2= 0.0823  
R1 = 0.0196 
wR2 = 0.0533 
R1 = 0.0500 
wR2 = 0.1099 
R indices (all data) R1= 0.0355, 
wR2= 0.0655 
R1 = 0.0405, 
wR2 = 0.0846 
R1 = 0.0211 
wR2 = 0.0545 
R1 = 0.0647 
wR2 = 0.1188 
Largest difference 
peak and hole (e·Å3) 
0.843 and -0.466 0.619 and -0.301 0.525 and -0.285 1.176 and -0.477 
aR1 = Σ||Fo| - |Fc||/Σ|Fo|; b wR2 = {Σ[w(Fo2– Fc2) 2]/Σ[w(Fo2) 2]}1/2; where w = q/σ2(Fo2) + (qp) 2 + bp. GOF = 
S = {Σ[w(Fo2– Fc2) 2]/(n – p)}1/2, where n is the number of reflections and p is the number of parameters 
refined. 
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2.5 Preparation of Modified Glassy Carbon Electrodes 
Complexes 2, 28, and 29 (4 mg each) were dispersed in 1 mL acetonitrile (VWR, 
ACS grade, dried using an MB-SPS from MBRAUN) using a vortex mixer (Vortex Genie 
2, Scientific Industries). The 10%  (v/v) aqueous nafion solution (12.5 μL) was then added 
to the resulting ink. The dispersion was further homogenized via ultrasonication (Cole-
Parmer Ultrasonic Bath) for 2 h. After sonication, 10 μL of the resulting dispersion was 
dropped onto a glassy carbon electrode (E4TQ ChangeDisk, Pine Research), rotating at 50 
RPM, affixed to a rotator (MSR Rotator, Pine Research). The rotation speed was 
subsequently increased to 300 RPM, and this speed was maintained until the film dried. 
2.6 Electrode Surface Characterization 
 Scanning electron microscopy (SEM) was carried out using a TESCAN VEGA3 
microscope operating at 10 kV and 10 mA. Images of the catalyst materials were taken 
using the ejectable glassy carbon electrode disk tip as the substrate. As above, catalyst 
dispersion was dropped onto the glassy carbon electrode and allowed to dry over rotation. 
At this point, either the disk was ejected and taken to the SEM, or the material was cycled 
to peak activity (as described above) before disk ejection and characterization. Raman 
spectroscopy was carried out using a Renishaw inVia spectrometer with red (632 nm) laser 
(Renishaw RL 633) operating at 100% power. Samples were prepared for Raman as 
described for SEM. 
2.7 MTT Assay 
 MTT assays were performed by Dr. Sarah Andres at the University of Louisville 
medical school in collaboration with Dr. Paula Bates. Anti-proliferative activity of 16-27 
were evaluated using a previously published 3-(4,5-dimethylthiazol-2-yl)-2,5-
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diphenyltetrazolium bromide (MTT) assay protocol.88-90 Cells were seeded in 
quadruplicate wells in 96-well plates and allowed to adhere overnight. To account for 
intrinsic differences in growth rates, cells were plated at the following densities to 
achieve comparable MTT absorbance values (OD570 between 0.5 and 1) for untreated 
cells: A549, 1000 cells/well; IMR-90, 5000 cells/well. After 72 h of treatment with test 
compounds, MTT (Sigma/Millipore Sigma, St. Louis, MO) was added for 4 h prior to 
cell lysis. Each assay was performed in at least triplicate. All readings were normalized to 
the vehicle treatment of only DMSO. 
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CHAPTER III 
SYNTHESES, STRUCTURES, AND ELECTROCHEMICAL STUDIES OF N,N'-
BIS(ALKYLTHIOCARBAMATE)BUTANE-2,3-DIIMINE CU(II) COMPLEXES AS 
PENDANT ALKOXY DERIVATIVES OF CU(ATSM) 
3.1 Introduction 
 The biological applications of 1 as a diagnostic and therapeutic agent have been 
extensively studied.22-31,38 The Cu(II) ion sits in a conjugated dianionic N2S2 framework 
with terminal –NHMe functional groups that do not participate in metal-ligand binding. 
The key structural and electronic facets of 1 that make it ideal for biological studies are its 
neutrality, planarity, and reduction potential. The rigid planarity of 1 is exemplified by the 
best fit plane for all 17 non-hydrogen atoms, for which the largest deviation ±0.047 Å for 
N2/N2′ with a standard deviation of ±0.025 Å.91 Along with the planarity, the complex is 
neutral and is capable of diffusing across cell membranes and is only retained by gaining a 
negative charge upon reduction. Compound 1 can therefore freely diffuse across cell 
membranes to either enter or exit a cell under normoxic conditions. However, under the 
low oxygen tension of hypoxia, 1 is reduced in the cytosol and thus preventing it from 
exiting the cell, Figure 3-1. This redox selectivity of 1 has led to its evaluation as a 64Cu 
and 62Cu radiopharmaceutical for selective imaging of hypoxia.27-31 
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Figure 3-1. Depiction of copper retention in normoxic (A) and hypoxic (B) cells. 
 Further, 1 has been evaluated for the treatment of neurodegenerative diseases.22-25 
Phase I clinical trials, as a therapeutic for amyotrophic lateral sclerosis/motor neuron 
disease (ALS/MND) are currently underway.26 The redox selectivity is further exemplified 
by comparison of 1 with the copper complexes of PTSM (+80 mV) and GTSM (+160 mV), 
Figure 3-2. The CuPTSM derivative with its more anodic CuII/I couple was found to not be 
retained in cells in a discriminating manner when compared to 1 for imaging. In 
therapeutics, the treatment of cancer cells have been evaluated comparing 1 with CuGTSM. 
Here however, it was found that 1 was ineffective in the treatment of cancer cells.38  
 
Figure 3-2. Structural comparison of CuATSM, CuPTSM, and CuGTSM.  
  
44 
  
 The biological importance of 1 has led to the synthesis and characterization of a 
large number of related copper bis(thiosemicarbazonato) complexes with symmetric and 
asymmetric variation at the R1 and R2 positions, shown in Scheme 3-1.
7,13,15,19,21,32-33,39-40,92 
Substitution at the R1 position has largely focused on other amine derivatives to investigate 
the impact on selectivity and/or reduction potential. In general, chain extension has a small 
effect on the CuII/I potential.13,15 However, modification with aromatic rings can lead to 
stabilization of Cu(I) by as much as +240 mV.39 Que and co-workers recently reported 
symmetric and asymmetric CuATSM derivatives with the –NHMe groups replaced by –
NHCH2CF3 with stabilization of Cu(I) by ~70 mV per –NHCH2CF3.
 Interestingly, these 
complexes allow for hypoxia imaging by 19F MRI, thus avoiding the need for 64Cu.32 
Variation of the R2 backbone methyl groups with hydrogen or phenyl substituents also 
stabilize Cu(I), with the later showing a larger effect of ~240 mV.13,39 The effect of R2 
group substitution for a wide variety of functional groups was evaluated using 
experimentally benchmarked density functional theory calculations of CuII/I reduction 
potentials. A Hammett analysis of the theoretical CuII/I potentials is consistent with an 
inductive effect where Cu(I) is stabilized by the electron-withdrawing substituents.16 
 
Scheme 3-1. Synthesis of compounds 10-15. 
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 The numerous derivatives of Cu(ATSM) reported to date have by and large 
maintained an N2S2 donor core with terminal amine based R1 groups. The research in this 
dissertation highlights a modification to the ligand framework by incorporation of alkoxy 
groups at the terminal R1 position. As outlined in Scheme 3-1, a series of six ligands and 
their Cu(II) complexes have been synthesized and fully characterized. One compound was 
previously synthesized and characterized by UV-visible spectroscopy.93 As detailed below, 
this results in a substantial shift in the Cu(II/I) reduction potential relative to 1.  
3.2 Results  
3.2.1 Synthesis and Characterization  
 A series of N2S2 N,N′-bis(alkylthiocarbamate)butane-2,3-diimine ligands (4 – 8) 
with varying O-alkyl chain lengths and N,N′-bis(methylthiocarbamate)hexane-3,4-diimine 
(9) have been prepared and complexed with Cu(II) yielding the square planar complexes 
10 – 15. The ligands were obtained in three steps from inexpensive bulk commodity 
chemicals, Scheme 3-2. 
 
Scheme 3-2. Synthesis of ligands 4-9. 
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Using previously reported methods, xanthates were prepared from the appropriate 
alcohol and carbon disulfide.79 The xanthates were subsequently condensed with hydrazine 
monohydrate to yield the hydrazinecarbothioc acid O-alkyl esters.80 Condensation of the 
ester with butanedione (4 – 8) or hexanedione (9) yielded the desired ligand in a reaction 
similar to H2ATSM synthesis.
14 Notably, all ligand syntheses were conducted open to the 
atmosphere in ethanol solution with facile purification by filtration and washing. The 
simplicity of these methods and the variety of available alcohols and diones make N,N′-
bis(alkylthiocarbamate)butane-2,3-diimine and its derivatives potentially useful new class 
of ligands related to the bis-thiosemicarbazone family. 
The 1H NMR of 4, seen in Figure 3-3, displays a prototypical chemical shift for 
methoxy protons at δ 4.03. This chemical shift is a key identifier for this ligand class of the 
protons adjacent to the oxygen near 4.00. The backbone protons occur at δ 2.11, which is 
another indication of condensation. A unique feature for this subset of ligands is the two 
chemical shifts at δ 11.46 and 11.77, corresponding to the imino hydrogen. BTSC analogs 
display only one peak for this hydrogen. This unique pattern could potentially arise from 
tautomerism, however temperature dependent NMR studies were not conducted. The 13C 
NMR of 4, Figure 3-4, shows prototypical peaks of tertiary C=N and C=S carbons at δ 
117.8 and 188.0, respectively. The methyl carbons of the backbone and alkoxy 
functionality are present at δ 58.5 and 12.3 respectively. The remaining 1H and 13C NMR 
spectra for 5-9 can be found in the appendix, Figures A1-A9.  
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Figure 3-3. 1H NMR of 4 in DMSO. 
 
Figure 3-4. 13C NMR of 4 in DMSO, with the ppm inset of a zoomed out image to display the 
DMSO peak.  
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The FT-IR spectrum of 4, Figure 3-5A, is representative for this class of 
compounds. Key stretches are the N–H, C–O, and C=S. The C–O and C=S occur at 1137 
and 1060 cm-1 in 4. The N–H stretch, at 3240 for 4, is paramount in identification. The 
corresponding hydrazinecarbothioc acid O-alkyl ester, has a primary and secondary amine, 
thus has multiple N–H stretches that are not present in the ligand. Further, the IR spectra 
of 10–15 display no N–H stretching, indicative of deprotonation, Figure 3-5B. The loss of 
these protons generates a 2– charge on the ligand, in turn creating a neutral chelate from a 
metal 2+ ion. Therefore, to generate a neutral complex, a suitable base is needed to de-
protonate the ligand framework. A suitable metal salt may contain a basic counter ion (i.e., 
acetate) or an exogenous base may be used. Further, the C–O and C=S stretches shift to 
1091 and 948 cm-1, respectively. Lastly, upon metalation, new peaks occur in the IR 
spectrum at 831 and 671 cm-1 that indicate Cu–S and Cu–N stretching. The remaining FT-
IR spectra can be found in the Appendix (Figures A10-A19). 
 
Figure 3-5. FT-IR spectra of 4 (A) and its copper complex 10 (B). 
The electronic spectra of 10 – 15 recorded in dichloromethane display a ligand to 
metal charge transfer band near 485 nm and two more intense ligand to ligand charge 
transfer bands near 248 and 290 nm. The spectrum of 10 is shown in Figure 3-6 as a 
representative of the whole class of compounds. The spectra of 11–15 can be found in the 
Appendix (Figures A20-A24). The transition energies are largely insensitive to the identity 
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of the O-alkyl group R1 or the backbone substituent R2, Table 3-1.  As shown in Table 3-
1, the high energy bands for 10 at 246 and 290 nm are red shifted by 2340 and 2640 cm-1 
with respect to the bands at 261 and 314 nm in Cu(ATSM), 1. The lower energy band of 
10 at 486 nm is blue shifted by 388 cm-1 relative to the band at 477 nm in Cu(ATSM).13 
The shifts are attributed to electronic differences within the ligand framework and no 
solvent effects. The spectra of 10 in DCM and DMSO are not substantially different.  
 
 
Figure 3-6. UV-visible spectrum of 10, representative of the class. 
 The EPR spectra of 10 – 15 were recorded as powders at room temperature. 
Complexes 10 – 15 are expected to be square planar with an unpaired electron in the dx2-y2 
orbital. The unpaired electron could undergo transitions to the dxy, dxz, and dyz orbitals. 
Since the dxz and dyz are degenerate in a square planar environment, only two transitions 
are expected to be observed with the dxz/yz transition twice the intensity. As shown in Figure 
3-7 complex 12 displays an axial spectrum with g|| > g > 2 (Table 3-1) consistent with 
square planar Cu(II) and a single unpaired electron located in dx2-y2.  The remaining spectra 
can be found in the Appendix (Figures A25-A29). Simulated values for g|| and g fall in 
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the narrow ranges of 2.031 – 2.042 and 2.089 – 2.131, respectively, consistent with the 
similarities observed for 11 – 15 in the electronic spectrum. The spectrum of 10 is too broad 
to resolve the axial signal, but the observed g-value of 2.061 is near the average g-values 
of the other complexes. 
 
 
Figure 3-7. Experimental (solid black line) and simulated (dashed red line) EPR spectrum of 12. 
This spectrum is representative of the whole class of compounds. 
 A comparison of the EPR and UV-visible data shows only small changes in the 
spectroscopic features of complexes 10 – 15 as compared to similar bis-thiosemicarbazone 
analogues, 1 and 30 – 33. The axial EPR spectra of 1, Cu(ATSM), is indistinguishable from 
those of 11 – 15. The reported g|| and g values of 2.115 and 2.038 for 1 fall within the 
narrow ranges of 2.031 – 2.042 and 2.089 – 2.131 for 11 to 15, Table 3-1, indicating no 
significant changes in the relative energies of the d-orbital manifold. 
3.2.2 Electrochemical Studies  
 The cyclic voltammograms of 10 – 15 in dichloromethane, each show two 
reversible events assigned to CuIII/II and CuII/I couples, Table 3-1. The E1/2 values for the 
  
51 
  
CuIII/II and CuII/I events of 10 are observed at +585 and –857 mV versus 
ferrocenium/ferrocene, respectively, Figure 3-8. The remaining voltammograms can ebe 
found in the  Appendix (Figures A30-A34). Variation of the side-chain R1 and backbone 
R2 groups modulates the Cu
II/I reduction potential. Increasing the length of the R1 from –
OMe to –OEt and –OnPr systematically decreases the CuII/I potential of 11 and 12 to –879 
and –892 mV, respectively. Further chain extension to –O-octyl, 14, slightly increases the 
potential to –884 mV. Substitution of –OnPr with –OiPr further destabilizes Cu(I) as 
indicated by the CuII/I potential of 13 at –904 mV. Changes at the R2 slightly influence the 
reduction potential as shown by a comparison of 11 and 15, with the former more difficult 
to reduce by 5 mV.  
  
 
Figure 3-8. Cyclic voltammogram of 10 in CH2Cl2 with 0.1 M tetrabutylammonium 
hexafluorophosphate as supporting electrolyte. Scan rate = 100 mV/s; potentials referenced 
versus Fc+/Fc. 
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 A comparison of the methylamine derivative 1 with the methoxy derivative 10 
shows a +253 mV shift in the CuII/I reduction potential. A similar shift of +241 mV is 
observed upon substitution of –NHEt (34) with –OEt (11). These large shifts can be 
attributed to an inductive effect consistent with the electron withdrawing properties of the 
alkoxides and prior Hammet analysis of the –NHR functional group effect on reduction 
potentials.16 Extension of the carbon chain in the R2 position from Me to Et results in a 5 
mV increase from compound 11 to 15, whereas the related bis-thiosemicarbazone 
analogues 1 and 36 show an increase of 10 mV confirming the new class of compounds 
follow the same electrochemical trend. This difference in reduction potential would 
indicate that this new class of compounds would not be ideal for imaging given the ease of 
accessibility. However in comparison with 35, which as previously mentioned has potential 
therapeutic properties, this new class of compounds has a more anodic CuII/I potential by 
approximately 100 mV. Thus, these compounds could be useful in the treatment of cancer. 
Unfortunately, these compounds are only soluble in DCM, which is not suitable for 
biological studies. In total, six new complexes with CuII/I reduction potentials in the range 
of -904 mV to -857 mV have been prepared demonstrating that substitution of –NHR with 
–OR yields a large anodic shift in the Cu(II/I). 
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Table 3-1. UV-visiblea, EPRb, and electrochemicalc data for N,N′-bis(alkylthiocarbamate)butane-2,3-diimine Cu(II) complexes 7 – 12 
and selected Cu(ATSM) derivatives. 
Complex R1 R2 max
a 
(nm) (ε) 
g||, g 
(gavg)b 
CuIII/II 
E1/2 (ipc/ipa 
(mV)c 
CuII/I 
E1/2 (ipc/ipa 
(mV)c 
Ref. 
10 OMe Me 246 (16,000) 290 (20,000) 
486 (2,680) 
(2.061) 585 (0.934) -857 (0.941) 77 
11 OEt Me 248 (16,300) 290 (22,700) 
485 (2,920) 
2.131, 2.036 (2.068) 528 (0.933) -879 (0.965) 77 
12 OnPr Me 248 (16,600) 291 (23,800) 
484 (2,930) 
2.127, 2.034 (2.065) 542 (0.964) -892 (0.997) 77 
13 OiPr Me 248 (16,500) 292 (23,600) 
484 (3,210) 
2.089, 2.042 (2.058) 505 (0.867) -904 (0.964) 77 
14 O-octyl Me 248 (15,900) 291 (23,600) 
485 (3,100) 
2.130, 2.034 (2.066) 545 (0.929) -884 (0.867) 77 
15 OEt Et 249 (18,300) 292 (25,000) 
485 (3,340) 
2.124, 2.031 (2.062) 549 (0.934) -874 (0.975) 77 
1 NHMe Me 261 314 477 2.113, 2.029 2.026 (2.056) 200 -1110 13a,c 8b 
30 NH2 Me 263 310 477 N/A -180 -1110 13 
31 NMe2 Me 320 450 490 525 2.085 2.033 2.024 (2.047) N/A N/A 8 
32 N(C4H8) Me 321 368 515 566 N/A N/A -1050 (1.03) 39 
33       NPhMe H 323 381 512 567 N/A N/A -700 (0.99) 39 
34 NHEt Me N/A N/A N/A -1120d 94 
35 NHMe H 194 262 324 495 N/A N/A -950 13 
36 NHMe Et 194 267 316 483 N/A 190 -1100 13 
a) Electronic spectra measured in CH2Cl2 (10 – 15), DMSO (1, 30, 35, 36), or DMF (31 - 33) solution  b) Powder EPR spectra collected 
on solids at room temperature (10 –15, 1, 31); gavg = 1/3[g|| + 2g]. c) Electrochemical potentials versus Fc+/Fc measured versus an internal 
standard in CH2Cl2 with 0.1 M nBu4NBF4 (10 – 15) or calculated from reported potentials versus Ag/AgCl in DMSO with 0.1 M nBu4NBF4 
(1, 30, 35, 36) or versus SCE in DMF with 0.1 M nBu4ClO4 (32, 33) using the following conversions: E1/2 = -0.52 for Fc+/Fc vs. Ag/AgCl 
in DMSO; = E1/2 = -0.51 for Fc+/Fc vs. SCE in CH2Cl2 (10 – 15), DMSO (1, 30, 35, 36), or DMF (32, 33). d) Reported as 10 mV more 
negative than 1. 
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3.2.3 Crystallographic Studies  
 X-ray quality diffraction crystals of 10 – 15 were obtained as orange needles or 
plates upon slow evaporation of a dichloromethane solution of the complex layered with 
ethanol. Crystal data and structure refinement details are listed in the Chapter 2, Tables 2-
2 to 2-3. All complexes crystallize as discrete, square planar Cu(II) complexes with no 
solvent molecules in the crystal lattice. An ORTEP representation of 10 is shown in Figure 
3-9 with selected bond distances and angles provided in Table 3-2. The structures of 11 – 
15 are highly similar to 10 with core structure bond distances and angles statistically 
indistinguishable from those in 10 (see Chapter 2 for CCDC deposit number). The 
following discussion of 10 is representative of the entire group of complexes.  
 
Figure 3-9. ORTEP95 view (50% probability) of 10 showing atom labeling for all non-hydrogen 
atoms in the asymmetric unit and symmetry generated (1-x, -y, 1/2-z) donor atoms. 
 The Cu of 10 occupies an N2S2 square plane provided by the N,N-
bis(methylthiocarbamate)butane-2,3-diimine ligand with Cu–N1 and Cu–S1 bond 
distances of 1.958(4) and 2.2498(12) Å, respectively. The S1 and N1 donors are symmetry 
generated as Cu1 sits on the special position (0.5, y, 0.25) in the orthorhombic space group 
Pbcn. A similar phenomenon occurs in 12, 14, 15, whereas in 11 and 13 the asymmetric 
unit contains independent atoms in the entire complex. Within the chelate ligand, bond 
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distances are consistent with a conjugated π-system. One bonding MO representation can 
be seen in Figure 3-10. The C3–S1, N1–N2, and C1–C1 bond distances of 1.741(5), 
1.384(5), and 1.484(8) Å, respectively, are typical of single C–S, N–N, and C–C bonds. 
The shorter N1–C1 and N2–C3 bond distances of 1.295(5) and 1.301(6), respectively, 
reveal C=N character. The sum of the four bond angles about the Cu is 360.0(3)°.  
 
Figure 3-10. Representation of the conjugated -network of the N,N′-
bis(alkylthiocarbamate)butane-2,3-diimine ligand of 10 highlighting localization of the C=N 
bonds. 
 
Table 3-2. Selected bond distances (Å) and bond 
angles (°) for 10 and 196 as representative 
examples of Cu(alkoxythiocarbamidates) and 
Cu(thiosemicarbazonates), respectively.a 
Bond Distance  10 1 
Cu-N1 1.958(4) 1.9584(16) 
Cu-S1 2.2498(12) 2.2453(5) 
N1-N2 1.384(5) 1.369(2) 
N1-C1 1.295(5) 1.300(2) 
N2-C3 1.301(6) 1.325(3) 
S1-C3 1.714(5) 1.760(2) 
C1-C1′ 1.484(8) 1.474(3) 
C3-O1 1.331(5)  
C3-N3b  1.338(3) 
Bond Angle   
N1-Cu-S1 85.00(11) 85.11(5) 
N1-Cu-N1′ 79.9(2) 80.61(7) 
S1-Cu-S1′ 110.12(7) 109.21(2) 
a) Atom labels for both complexes correspond to the 
numbering scheme of 10 in Figure 1. b) N3 is the 
nitrogen of R1 group NHCH3.  
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 Complex 10 is rigorously planar with the largest deviation from the best fit plane 
of all 17 non-hydrogen atoms of ±0.118 Å for C3/C3 and a standard deviation of only 
0.061 Å. This high degree of planarity extends throughout the whole range of complexes 
including the –O-octyl derivative, 14 (Figure 3-11). For 14, the best fit plane of all 31 non-
hydrogen atoms of ±0.364 Å for C4/C4 and a standard deviation of 0.258 Å. A comparison 
of the structural parameters of 10 and 1 provide a representative example of the similarities 
and differences of the N,N-bis(alkylthiocarbamate)butane-2,3-diimine and bis-
thiosemicarbazone complexes. The selected bond distances and angles in Table 3-2 reveal 
a highly similar structural core. The Cu–N1 and Cu–S1 bond lengths in 10 of 1.958(4) and 
2.2498(12) Å, respectively, are statistically equivalent with the values of 1.9584(16) and 
2.2453(5) Å in 1. Within the ligand framework, the bond distances are also statistically 
similar. Both complexes exhibit bond distances consistent with alternating single and 
double bonds in an extended conjugated network as depicted in Figure 3-9 for 10. A 
comparison of bond angles associated with the metal-ligand core of 10 and 1 reveals values 
that are statistically equivalent or that vary less than one degree.  
 
Figure 3-11. ORTEP95 view (50% probability) of 14 showing atom labeling for all non-hydrogen 
atoms in the asymmetric unit and symmetry generated (1-x, -y, 1/2-z) donor atoms. 
 The degree of structural similarity makes these compounds promising for biological 
applications. As previously established, the structural properties of 1 and analogous 
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compounds make these BTSC’s suitable for diagnostic and therapeutic uses. The 
electrochemical properties distinguish compounds as suitable or unsuitable for therapeutic 
and diagnostic uses. Thus rendering the ability to maintain structural integrity with 
variation in the reduction potential crucial for further development of this class of 
compounds. 
3.3 Conclusions 
 In summary, a new class of N,N-bis(alkylthiocarbamate)butane-2,3-diimine 
ligands and their Cu complexes have been reported as derivatives of bis-
thiosemicarbazones. Substitution of the terminal –NHR functional group with –OR allows 
tuning of the CuII/I and CuIII/II reduction potentials with minimal impact on the physical and 
electronic structures of the complexes. The lack of appropriate solubility limits their 
biological applications and restoration of a hydrogen bond donor may increase the 
solubility in desired solvents. The ease of synthesis of these new ligands and the wide 
variety of commercially available alcohols and diones provides for a large variety of new 
bis-thiosemicarbazone like complexes for future development. Notably, the synthetic 
methodologies developed in this work will be applied in the synthesis of the hybrid 
complexes discussed in Chapter 5. The hydrazinecarbothioc acid O-alkyl esters can be 
condensed with a mono-keto-thiosemicarbazide to generate the hybrid complex. 
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CHAPTER IV  
EFFECT OF STACKING INTERACTION ON THE TRANSLATION OF 
STRUCTURALLY RELATED BIS-THIOSEMICARBAZONE NI(II) HER 
CATALYSTS TO MODIFIED ELECTRODE SURFACES 
4.1 Introduction 
Increasing worldwide demand for cheap energy has fueled the need to develop 
sustainable alternative energy sources.97 Hydrogen offers great potential as a carbon-free 
alternative to fossil fuels.98 One of the major challenges in this area is the development of 
artificial water splitting catalysts based on solid state materials and molecular based 
electrocatalysts that efficiently produce O2 and H2 from water utilizing either solar 
energy99-102 or electrolysis.103-104 Platinum based catalysts are the gold standard catalyst for 
HER in aqueous acidic solutions. However, its practical widespread utility in 
electrocatalytic devices is limited by its scarcity and high cost.105-106 This has stimulated 
development of new electrocatalysts containing earth-abundant transition metals, such as 
Fe,107 Co,108-110 Ni,111-114 Cu,115 and Mo,116-118 as metal phosphides,108,119 selenides,120 
sulfides,121-122 and small molecule complexes.12,34-35,74,123-125 Of these materials, 
molybdenum sulfides stand out as an economical alternative to Pt.126-128 Their high activity 
is thought to arise from the location and number of cis-sulfur edge sites in their layered 
structures.128  
There is consensus that most homogenous molecular electrocatalysts generate 
reactive metal-hydride intermediates during HER.35,129-132 Several of these electrocatalysts 
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display low overpotential, high turnover frequencies, and Faradaic efficiencies in 
excess of 90%.132-133 There is an emerging interest in the modification of electrode surfaces 
with small molecule HER catalysts.109-110,134-136 Most notable, Fontecave and coworkers 
developed multi-walled carbon nanotube [Ni(PPh2N
Ph
2)2] modified electrodes that display 
high catalytic activity at low overpotential.29 The Grapperhaus lab previously reported the 
translation of activity and mechanism of a rhenium-thiolate HER catalyst from solution to 
modified electrodes.137 Other examples of heterogeneous molecular catalysts for HER 
include Co(dmgBF2)2(CH3CN)2)/carbon black (CB)/Nafion coated GC 
135 and 
cobaloximes modified electrodes,135-136 as well as, cobalt porphyrin,138 metal-
phthalocyanine,139-142 and an organometallic complex incorporated in a Nafion film.143 
However, these complexes either require high overpotential and/or are unstable over 
prolonged electrolysis reducing their practical use as HER catalysts.  
Recently, the Grapperhaus lab and others have explored the use of 
thiosemicarbazone ligands in the design of new HER electrocatalysts.10,12,34-35,76 The 
thiosemicarbazone ligands are redox non-innocent and can function as a reservoir for 
charge with hydrogen evolution at either the metal or ligand. The HER mechanism 
proceeds via ligand-assisted metal-centered,144 ligand-centered,10,145-146 or metal-assisted 
ligand-centered reactivity depending on the identity of the metal.74,145,147 Herein, in 
collaboration with Alex Gupta and Dr. Gautam Gupta of the University of Louisville 
Engineering School, we report the synthesis, characterization, and electrocatalytic behavior 
of a series of structurally related bis-thiosemicarbazone Ni(II) complexes, deposited on 
carbon electrode surfaces. The ligands are obtained in high yields using readily available, 
inexpensive organic reagents according to literature methods.8,32 The resulting Ni(II) 
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complexes have been characterized by NMR, FT-IR, and UV-vis spectroscopies, X-ray 
crystallography, and cyclic voltammetry in acetonitrile prior to deposition on glassy carbon 
electrodes (GCEs). Drop casting acetonitrile solutions of the Ni complexes on GCEs 
produce uniform coatings that were characterized by spectroscopic and microscopy 
methods before and after HER catalysis in aqueous acidic solutions. 
4.2 Results 
4.2.1 Synthesis and Characterization 
The ligands H2ATSM,
8 H2ATSDM,
32 and H2ATSM-F6
32 were prepared as 
previously reported. The Ni(II) complexes 2, 28, and 29 were synthesized using the 
established methodology for the preparation 2.8 The newly reported 28 and 29 were 
characterized by elemental analysis, cyclic voltammetry, mass spectrometry, and NMR, 
FT-IR, and UV-visible spectroscopies. The 1H NMR spectra of 28 and 29, Figure 4-1 top 
and bottom respectively, are consistent with their proposed structures. The protons of the 
methyl group of the backbone, remained largely unchanged between 28 and 29 with δ 
values of 1.87 and 1.94 respectively. The terminal methyl protons of 28 (δ 3.10) are 
substantially upfield of the methylene protons of 29 (δ 4.00). Lastly, 29, displayed the 
amine proton at δ 8.28. This proton is not observed in 28 due to the presence of the dimethyl 
functionality, giving rise to the integration of the peak at δ 3.10 being twice that of 1.87. 
 The IR spectra of 28, Appendix, Figure A35 lacks the N–H stretching, indicative 
of chelation, because the metal displaces the proton. Further, it is concluded by the presence 
of Ni–S and Ni–N stretches at 900 and 783 cm-1, respectively, that the metalation was 
successful. The FT-IR of 29, Figure 4-2, displays the prototypical N–H stretch at 3462 cm-
1 due to the presence of the pendant secondary amine. The –CF3 functionality gives rise to 
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a C–F stretch at 1138 cm-1. Lastly, there is again the Ni–S and Ni-N stretches at 941 and 
832 cm-1 respectively. 
 
 
Figure 4-1. 1H NMR of 28 (top) and 29 (bottom) in DMSO. 
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Figure 4-2. FT-IR of 29 as a powder (ATR). 
All of the complexes gave green solutions in acetonitrile. The ligand-to-ligand 
charge transfer transitions8 in the UV-visible spectrum slightly increase in energy from 28 
(411 and 436 nm) to 2 (398 nm) to 29 (392 nm), Figure 4-3. The change in the ligand to 
ligand charge transfer band exemplifies the effect of the functional group of the pendant 
amine. The energies increase from the most electron donating group, dimethyl, to the 
electron withdrawing group, –CH2CF3. Further, the ligand to ligand charge transfer band 
for 28 displays two λmax values at 411 and 436 nm. This feature appears to be absent in 2 
and 29; however, the peak of 2 at 398 nm appears asymmetrical, indicating the possibility 
of a similar effect of two ligand-to-ligand charge transfer bands present. The spectrum of 
29 does not readily display this feature. All complexes display similar π to π* transitions 
at 256 nm. 
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Figure 4-3. UV-visible spectra of 2 (black dots), 28 (solid blue), and 29 (dashed red) in 
acetonitrile. 
4.2.2 Crystallography 
The solid state structures of 28 and 29 were determined by single crystal X-ray 
diffraction for comparison with the known structure of 2.96 Crystals of 28 and 29 were 
obtained as orange prisms and red brown plates, respectively, via slow evaporation of an 
acetonitrile solution layered with ether. Crystallographic data and structure refinement 
details are listed in the Chapter 2, Table 2-4. The crystal lattices of 2 and 29 include an 
acetonitrile molecule, while the lattice of 28 is not solvated. 
The ORTEP95 representations of 28 and 29 in Figure 4-4(top) and 4-4(bottom), 
respectively, show that each contains a square planar Ni(II) in an N2S2 donor environment. 
Selected bond distances and angles for 2, 28, and 29 are provided in Table 4-1. The Ni–N 
distances are statistically equivalent over the series with an average value of 1.856(5) Å. 
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Further, there is no significant differences in the Ni–S bond distances, which have an 
average value of 2.1568(18) Å. The similarities in metric parameters are also observed in 
the bond distances within the ligand framework. For all three Ni complexes, the bond 
distances are consistent with a conjugated π-system of alternating single and double bonds.  
 
Figure 4-4. ORTEP95 view (50% probability) of 28 (top) and 29 (bottom) showing atom labeling 
for all non-hydrogen atoms in the asymmetric unit.  
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Overall, the structures of 2, 28, and 29 are best described as square planar. Both 2 
and 28 are rigorously planar with all non-hydrogen atoms in or near the best-fit plane. For 
2, the best fit plane of all 17 non-hydrogen atoms has a standard deviation of ±0.032 Å 
with the largest deviation of ±0.067 Å for S2. Similarly, in 28, the standard deviation from 
the best fit plane of all 19 non-hydrogen atoms is ±0.053 Å with the largest deviation of 
±0.126 Å for C3. The pendant –CH2CF3 groups of 29 disrupt the overall planarity of that 
molecule. However, with the exception of the –CF3 moieties the non-hydrogen atoms 
define a plane with a standard deviation of ±0.033 Å and a largest deviation of ±0.083 Å 
for S2. The –CF3 carbon atom C8 sits 1.46 Å above the best fit plane for 29, whereas C10 
lies 1.43 Å below the plane. The deviation of planarity caused by the CF3 moiety can be 
seen in Figure 4-5. 
Table 4-1. Selected bond distances (Å) and bond angles (°) for 2,96 28, and 29.  
Bond distance 2a 28 29 
Ni–N1 1.861(2) 1.8528(8) 1.854(3) 
Ni–N3 1.855(2) 1.8580(8) 1.863(3) 
Ni–S1 2.1546(6) 2.1617(3) 2.1542(11) 
Ni–S2 2.1598(7) 2.1576(2) 2.1527(10) 
S1–C5 1.767(3) 1.7665(9) 1.763(4) 
N2–C5 1.315(3) 1.3222(12) 1.308(5) 
N1–N2 1.378(3) 1.3694(11) 1.381(4) 
N1–C1 1.303(3) 1.3038(11) 1.310(5) 
C1–C3 1.489(4) 1.4857(13) 1.487(5) 
C1–C2 1.470(3) 1.4658(13) 1.474(5) 
N5–C5 1.339(3) 1.3456(12) 1.350(5) 
N5–C7 1.449(3) 1.4570(13) 1.440(5) 
Bond angle    
N1–Ni–S1 87.07(6) 87.09(3) 87.35(10) 
N1–Ni–N3 83.59(9) 83.66(4) 83.65(13) 
S2–Ni–S1 101.81(3) 102.019(10) 101.94(4) 
aMetric parameters for 2 are reported according to the atom labeling scheme in Figure 
4-4, which differs from prior structural report.96 
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Figure 4-5. Ball and stick representation of 29 exemplifying the deviation of planarity caused by 
the CF3 group. 
 
The crystal packing arrangements for the rigorously planar 2 and 28 display similar 
columns of paired complexes stacked along the a-axes, Figure 4-6. The bulkier –CH2CF3 
groups in 29 preclude complex pairing resulting in long range stacking along the b-axis. 
For 2, the “inverse pair” of complexes containing Ni (x, y, z) and Ni′ (1 – x, 1 – y, 1 – z) 
stack with an interplanar distance of 3.48 Å. These inverse pairs form a column of 
complexes generated by translation along the a-axis. The interplanar distance between Ni′ 
(x, y, z) and Ni′′ (1 + x, y, z) is 3.47 Å. Neighboring columns, with equivalent spacings, are 
generated by the 21 screw axis (Ni′′′) and c-glide (Ni′′′′) associated with the P21/c space 
group. Complex 28, which crystallizes in the space group P-1, displays similar columns 
generated by translation of the inverse pair Ni (x, y, z) and Ni′ (1 – x, 1 – y, 1 – z) along the 
a-axis with interplanar distances of 3.54 and 3.37 Å for Ni/Ni′ and Ni′/Ni′′, respectively. 
The crystal packing of 29 is unique as the bulkier –CH2CF3 groups prevent stacking of 
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inverse pairs. As shown in Figure 4-6, Ni (x, y, z) and Ni′ (1 – x, 1 – y, 1 – z) are contained 
in separate, neighboring columns directed along the b-axis. In contrast to 2 and 28, the 
interplanar distances for the columns of 29 are long, 9.40 Å, as each member of the column 
is generated by a translation in the b-direction. 
 
Figure 4-6. Packing diagrams for 2 (top), 28 (middle), and 29 (bottom). Individual labels are 
associated with the following symmetry operations: Ni, E (x, y, z); Ni′, i (1 – x, 1 – y, 1 – z), Ni′′, 
translation along a (1 + x, y, z) for 2 and 28 or along b (x, 1 + y, z) for 29; Ni′′′, 21 (1 –x, 0.5 + y, 1.5 
- z); Ni′′′′, c-glide (x, 1.5 - y, 0.5 + z).  
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4.2.3 Homogeneous Electrochemical Characterization 
Cyclic voltammograms of 2 and 28 – 29, Figure 4-7, show two reversible events at 
potentials more cathodic than -1.3 V vs. Fc+/Fc in acetonitrile containing 0.1 M 
tetrabutylammonium hexafluorophosphate (TBAHFP) as supporting electrolyte. Density 
Functional Theory calculations performed by Artero and co-workers35 assigned the more 
anodic event to a ligand-centered reduction and the more cathodic event to the Ni(II/I) 
redox couple, Table 4-2. The ligand and metal centered E1/2 values for 2 occur at –1.73 V 
and –2.31 V vs. Fc+/Fc, respectively. The pendant secondary amines of 2 are replaced with 
tertiary amines in 28 resulting in an ∼30 mV cathodic shift in the ligand-centered reduction 
potential, –1.76 V. This is similar to corresponding 20 mV shift observed for CuATSDM 
relative to CuATSM.13 The Ni(II/I) event of 28 does not shift compared to 2. The –CH2CF3 
functionalities of 29 result in a 160 mV anodic shift of the ligand-centered event to –1.57 
V. The Ni(II/I) couple of 29 is similarly shifted to –2.18 V. The magnitude of the shift is 
in good agreement with Que and co-workers’ copper derivatives, which displayed ∼70 mV 
anodic shift per –CF3 group when compared to CuATSM.
32 
 
Figure 4-7. Cyclic voltammograms of 2 (black trace), 28 (blue trace), and 29 (red trace) in 
acetonitrile at 1 mM concentration with 0.1 M TBAHFP as supporting electrolyte. Scan rate = 200 
mV/s; potentials referenced versus Fc+/Fc. 
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4.2.4 HER Activity of Modified Electrodes 
Modified electrodes GC-1 – GC-3 were prepared by mixing 4 mg of 2, 28, or 29 
respectively, and 12.5 μL of a 10% aqueous Nafion solution with 1 mL acetonitrile. The 
resulting suspension was homogenized via ultrasonication, and 10 μL of the suspension 
was applied dropwise to the surface of a glassy carbon electrode. The suspension was 
allowed to dry on the electrode with rotation at approximately 300 RPM. The freshly 
prepared modified electrodes required high overpotential of ~700 – 750 mV to reach a 
current density of 10 mA/cm2 (the metric for comparing catalysts for water-splitting 
applications148-149) upon immersion in 0.5 M H2SO4 indicating poor initial catalytic 
activity.  
The modified electrodes were then conditioned by reductive cycling. For GC-1 the 
overpotential decreases from 0.697 V to 0.451 V, Figure 4-8A. Similarly, the overpotential 
for GC-2 decreases from 0.703 V to a minimum of 0.446 V, Figure 4-8B. The large shift 
of ~0.250 V represents a dramatic improvement in catalytic efficiency. Prior to 
conditioning, the Tafel slopes for GC-1 and GC-2 are 91 and 72 mV/decade, respectively. 
Following conditioning, the Tafel slopes for GC-1 and GC-2 increase only slightly, 
Figures 4-8D and 4-8E, suggesting the mechanism has not significantly changed. In 
contrast, conditioning does not improve the overpotential for GC-3, Figure 4-8C. In fact, 
the Tafel slope for GC-3, Figure 4-8F, increases dramatically from 53 to 167 mV/decade 
Table 4-2. Reduction potentials versus Fc+/Fc and peak separation for 2 and 28– 29 in 
acetonitrile containing 0.1 M TBAHFP as supporting electrolyte. 
Complex L/L- E1/2 (V) ΔE (mV) Ni(II/I) E1/2 (V) ΔE (mV) 
2 –1.73 (78) –2.31 (84) 
28 –1.76 (68) –2.31 (73) 
29 –1.57 (67) –2.18 (78) 
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upon reductive cycling. This drastic change in electrode kinetics can be attributed to either 
a change in the active site or leaching of 29 into the electrolyte. 
 
Figure 4-8. Effects of reductive cycling from 0 to -0.8 V vs. RHE at 50 mV/sec on the performance 
of the three modified electrodes. (A) polarization curves for GC-1 exhibits peak HER performance 
after 300 cycles. (B) polarization curves for GC-2 exhibits peak HER performance after 200 cycles. 
(C) polarization curves for GC-3 exhibits peak performance after 1000 cycles. (D) Tafel slopes for 
GC-1 before and after 300 cycles. (E) Tafel slopes for GC-2 before and after 200 cycles. (F) Tafel 
slopes for GC-3 before and after 1000 cycles. 
The experimentally determined Tafel plot is taken as the tangent to the onset region 
of the polarization curve. The onset region is traditionally defined as the region where the 
current is increasing while in between values of 0.5–2 mA/cm2. The slope of this line is 
dictated by the equation 𝑠𝑙𝑜𝑝𝑒 =
−𝛼𝑛𝐹
2.3𝑅𝑇
 where R,T, n, F, and α are the ideal gas constant, 
absolute temperature, moles of electrons transferred, Faradays constant, and transfer 
coefficient. For heterogeneous HER, Tafel plots provide insight into the mechanism of 
catalysis. From the determined Tafel slope, the rate-determining step is determined. The 
first step of any heterogeneous HER reaction is the Volmer step (120 mV/decade) which 
is the absorption of a proton to the modified electrode surface. From here, the mechanism 
can proceed one of two ways if the Volmer step is not rate limiting. The catalysis can 
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involve the adsorbed hydrogen reacting with a free proton in solution, Heyrovsky step (40 
mV/decade) or combination of two absorbed hydrogen atoms, Tafel step (30 mV/decade) 
to evolve H2, as seen in Scheme 4-1.  
 
 
Scheme 4-1. Representations of the rate determining steps for heterogeneous HER and their 
corresponding Tafel slopes. 
Extended reductive cycling beyond the point of conditioning was used to probe the 
stability of GC-1 – GC-3, Figure 4-8. No significant changes in Tafel slopes were observed 
over long-term cycling, suggesting no change in reaction kinetics.150 Only a minor increase 
in overpotential, ~40 mV, was observed, consistent with a small amount of catalyst 
leaching into the electrolyte. For GC-1, the overpotential increases from the optimized 
value of 0.451 V after 300 cycles to 0.486 V after a total of 1000 cycles, Figure 4-9A. 
Similarly, for GC-2 the overpotential increases from 0.446 V after 200 cycles to 0.499 V 
after 1000 cycles, Figure 4-9B. After 1000 total cycles, the Tafel slopes for GC-1 and GC-
2, Figure 4-9D and 4-9E respectively, increase slightly. For GC-3, the overpotential 
increases from 0.740 V after 1000 cycles to 0.780 V after 1500 cycles, Figure 4-9C, with 
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no significant change in Tafel slope, Figure 4-9F. The relative consistencies of the 
overpotential and Tafel slope over extended reductive cycling indicates this class of 
modified electrodes exhibits high durability for HER catalysis.  
A comparison of modified electrode performance for GC-1 – GC-3 at peak 
electrochemical activity is summarized in Figure 4-10. The polarization curves, Figure 4-
10A, show negligible differences in HER overpotential for GC-1 and GC-2. Both of these 
modified electrodes are superior to GC-3 by nearly 0.3 V. The Tafel slopes, Figure 4-10B, 
for GC-1 and GC-2 of 97 mV/dec and 89 mV/dec, respectively, suggest that neither proton 
adsorption or H2 diffusion from the active sites are rate limiting steps.
117,151 The rate-
limiting step is most likely the reaction of a solution proton with Ni-bound hydride to form 
H2 gas. The large Tafel slope of 167 mV/dec for GC-3 that implies proton adsorption is 
the rate-limiting step for HER catalyzed by this modified surface.152  
 
Figure 4-9. Effects of reductive cycling from 0 to -0.8 V vs. RHE at 50 mV/sec on the performance 
of the three modified electrodes past peak activity. (A) polarization curves for GC-1, revealing that 
its performance diminishes following 300 cycles. (B) polarization curves for GC-2, revealing that 
its performance diminishes following 200 cycles. (C) polarization curves for GC-3, revealing that 
its performance diminishes following 1000 cycles. (D) Tafel slopes for GC-1 at 300 and 1000 
cycles. (E) Tafel slopes for GC-2 at 200 and 1000 cycles. (F) Tafel slopes for GC-3 at 1000 and 
1500 cycles. 
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20  
Figure 4-10. HER performance of three nickel compounds evaluated following reductive cycling 
to the point of peak catalytic activity. Polarization curves (A) show the onset of hydrogen evolution 
and the overpotential required for each modified electrode to reach a current density of 10 mA/cm2. 
Tafel plots (B) show the current response to increasing overpotential throughout the onset period.  
 
This poor activity of 29 was perplexing since the mechanism of the NiBTSC’s is 
proposed to be reduction first. This should then lead to 29 being the best catalyst since its 
reduction potentials are significantly more accessible than the other two catalysts. 
However, these assumptions are predicated on homogeneous catalysis. To investigate if 29 
displayed better performance in homogeneous systems, 2, 28, and 29 were subjugated to 
identical homogeneous catalysis conditions, Figure 4-11. 
 
Figure 4-11. Cyclic voltammograms of 2 (black trace), 28 (blue trace) and, 29 (red trace) in 
acetonitrile at 1 mM concentration, with 0.1 M tetrabutylammonium hexafluorphospate supporting 
electrolyte, 16 μL of acetic acid at a scan rate of 200 mV/s. 
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 From Figure 4-11 it is observed that under identical conditions, 29 displays a slight 
cathodic shift in peak catalytic current. Interestingly, 29, has a more anodic reduction event 
after -1.5 V compare to that of 2 and 28. Overall, these differences are minute and would 
not lead to the substantial differences in HER activity upon deposition on an electrode 
surface. Recently, Zhang et al. examined the effect of the electrode surface before and after 
reductive cycling of BTSC catalyst which revealed significant changes in morphology.77 It 
is believed the surface morphology changes cause the drastic differences.  
4.2.5 Surface Characterization of Modified Electrodes  
 To investigate the effect of conditioning by reductive cycling, the surfaces of GC-
1 – GC-3 were visually characterized using SEM. Prior to conditioning, the images of GC-
1, Figure 4-12A, and GC-2, Figure 4-12B, show microcrystalline coatings. The crystal 
morphology is the same as the single crystals of 2 and 28 investigated by X-ray diffraction. 
The deposited compounds were cycled to their peak activity as established previously, to 
examine the surface at optimum catalysis. After conditioning, the surface of GC-1 lacks a 
crystalline appearance and resembles an amorphous microporous network, Figure 4-12D. 
A similar trend is observed for GC-2. Although the overall crystalline appearance remains 
intact after conditioning, Figure 4-12E, there is observable degradation of the crystalline 
edges and faces, Figure 4-13. In both cases, conditioning disrupts the crystal packing and 
reorders the catalyst on the electrode with an increase in surface area, which results in more 
exposed active sites. The morphology of GC-3 is very different from that of GC-1 and 
GC-2. Prior to conditioning, the appearance of the GC-3 surface, Figure 4-12C, is 
reminiscent of the thin plates of 29 used for single crystal X-ray diffraction studies. 
Following conditioning, the surface structure displays a fractured, plate-like appearance 
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(Figure 4-12F) consistent with loss of complex from the surface and diminished catalyst 
coverage. 
 
Figure 4-12. Scanning electron microscopy characterization of nickel compound films on glassy 
carbon electrodes before and after reductive cycling (0 to -0.8 V vs. RHE, 50 mV/sec) to peak 
activity. All scale bars correspond to 50 μm. (A) shows GC-1 before reductive cycling. (B) shows 
GC-2 before reductive cycling. (C) shows GC-3 before reductive cycling. (D) shows GC-1 after 
300 cycles. (E) shows GC-2 after 200 cycles. (F) shows GC-3 after 1000 cycles. 
 
Figure 4-13. Scanning electron microscopy image of GC-2 after reductive conditioning. 
Image taken after reductive cycling (0 to -0.8 V vs. RHE, 50 mV/sec) to peak activity (200 cycles) 
highlights the fusion of crystals after cycling. Scale bar corresponds to 10 μm. 
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 The surfaces of GC-1 – GC-3 were further studied by Raman spectroscopy before 
and after conditioning, Figure 4-14. The Raman spectra for GC-1 and GC-2 before 
conditioning match those for powder samples of 2 and 28, respectively, confirming the 
successful translation of the intact complex to the GC surface. Following conditioning, the 
Raman spectra of GC-1 and GC-2 retain peaks associated with 2 and 28 clearly 
demonstrating the complexes remain on the surface. In contrast, for GC-3 before 
conditioning show intense Raman signals corresponding to the D, G, and G’ bands of 
glassy carbon in addition to peaks associated with powder samples of 29. Following the 
reductive conditioning, the peaks associated with 29, such as the band at 1500 cm-1, are 
absent and only peaks associated with glassy carbon are observed.  
 This is attributed to poor initial coverage of the GC surface with substantial 
loss of catalyst upon reduction. The desorption of 29 is supported by the similar 
electrochemical activities of GC-3 following conditioning and bare GCE, Figure 4-15. 
Electrochemical impedance spectroscopy (EIS) was used to study the effect of conditioning 
on the electrical properties of the modified electrode surface. The impedance data was 
interpreted using an equivalent circuit model, Figure 4-16, consisting of the resistance of 
solution and wires (Rs) in series with an interfacial constant phase element (CPE) and a 
charge transfer resistance (Rc) circuit in parallel along with a Warburg element (W). The 
CPE is a circuit element used to replace a capacitor and is generally associated with a non-
homogeneous surface and variable current density at the electrode. The impedance of the 
CPE is defined as:  
ZCPE = 1(jω)
−n/𝑄 
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where Q is the magnitude of the CPE, j is the imaginary unit, ω is the angular frequency, 
and n is the CPE exponent. The Warburg element was introduced to account for diffusion 
resistance within crystalline domains, which are dominant prior to reductive cycling. 
Details are reported in the appendix, Table A1. 
 
Figure 4-14. Raman spectra of 2, 28 – 29 and GC1 – GC3 before and after conditioning. Spectra 
were taken before and after reductive cycling (0 to -0.8 V vs. RHE, 50 mV/sec) to peak activity 
and nickel compound powders on glass slides. (A) shows powdered 2 (purple trace), GC-1 before 
cycling (green trace) and GC-1 after cycling (black trace). (B) shows powdered 28 (purple trace), 
GC-2 before cycling (green trace), and GC-2 after cycling (red trace). (C) shows powdered 29 
(purple trace), GC-3 before cycling (green trace), and GC-3 after cycling (blue trace). 
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Figure 4-15. Polarization curves for bare glassy carbon (black trace) GC-3 prior to conditioning 
(green trace) and GC-3 after conditioning (purple trace). 
 
Figure 4-16. Equivalent circuit model used to fit EIS data. 
 Prior to conditioning, the Nyquist plots for GC-1 – GC-3 (Figure A36-A38) show 
large charge-transfer resistance (Rc) values. The resistance for GC-3, 34,500 Ω, is larger 
than GC-1, 25,100 Ω, and GC-2, 18,800 Ω. Following conditioning of 300 and 200 cycles, 
respectively, the charge transfer resistance for GC-1 and GC-2 drop substantially to 270 
and 160 Ω, respectively. This dramatic decrease indicates excellent charge transfer kinetics 
between the film and electrode attributed to a reorganization of active sites to improve 
contact with the electrode and solution. In contrast, GC-3 does not exhibit significant 
change in charge transfer resistance upon conditioning and remains large, 34.0 kΩ. 
Extended cycling to probe durability shows a slight increase in the charge transfer 
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resistance for GC-1 and GC-2 to 370 and 420 Ω, respectively. This change is attributed to 
a decrease in the number of active sites due to leaching and is consistent with the small 
increase in overpotential. 
 The combined surface characterization techniques confirm morphological changes 
of the catalyst coatings associated with a decrease in charge transfer resistance upon 
exposure to reductive cycling. For GC-1 and GC-2, conditioning reorganizes the 
microcrystalline domains as an open network arrangement which ostensibly allows for 
greater solvent access and ion permeability. For GC-3, the initial catalyst film shows poor 
electrode coverage and reductive cycling results in significant loss of catalyst by 
delamination.  
4.3 Conclusions 
 The immobilization of active homogeneous HER catalysts on electrode surfaces 
has garnered recent attention. A fundamental aspect of these studies is the ability to 
translate homogeneous solution phase activity to heterogeneous systems supported on an 
electrode. In homogeneous systems, the HER activity is largely dependent on the electronic 
structure of the catalyst, which dictates reduction potential and interactions with charged 
substrate. The physical structure can also be important as demonstrated in catalysts with 
pendant amines that help orient substrate for reduction. However, in heterogeneous systems 
derived from small molecule catalysts the physical structure is an essential component as 
it relates to catalyst-electrode interactions and charge transfer between electrode, catalyst, 
and substrate. 
 The impact of small physical changes in electronically similar HER catalysts on the 
ability to translate activity from homogeneous to heterogeneous solution has been 
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demonstrated from the evaluation of 2, 28, and 29. A remarkable feature of this NiBTSC 
system is the good stability of the surface adhered catalysts without inclusion of covalent 
linkers to the surface. The non-covalent interactions between the catalyst and the electrode 
allow dynamic reorganization upon reductive cycling, Scheme 4-2. Complexes 2 and 28 
are rigorously planar with the strong stacking interactions observed in single crystals, while 
the introduction of a –CH2CF3 side chain disrupts stacking interactions in the solid state of 
29. The strong stacking interactions in 2 and 28 lead strong interaction between GC and 
the catalyst and films dominated by microcrystal domains. Upon reductive cycling, these 
domains reorganize with increased surface area and improved contact between electrode 
and solution. In contrast, the absence of stacking ability for 29 leads to poor initial electrode 
coverage and delamination upon reductive cycling. The results underscore the importance 
of physical, solid state structure for the translation of homogeneous catalysts to solid 
support and demonstrate how packing interactions in the crystal structure can be used to 
help discriminate between catalysts with similar electronic structures.  
 
Scheme 4-2. Conditioning via reductive cycling. 
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CHAPTER V  
SYNTHESIS, CHARACTERIZATION, AND BIOLOGICAL ACTIVITY OF NOVEL 
ASYMMETRIC BIS-THIOSEMICARBAZONE DERIVATIVES 
5.1 Introduction 
The treatment of cancer has included surgery,153-156 hormone therapy,157-160 
radiation,161-164 immunotherapy,165-169 and chemotherapy.170-173 Each of these treatments 
come with side effects, with the most troublesome being the lack of selectivity between 
cancerous and healthy cells. The drive to develop a cancer therapeutic that discriminates 
in its apoptotic inducing behavior, has led to a new approach of targeted therapy. A 
prominent targeted therapy is the use of monoclonal antibodies;174-178 however, even this 
is not without side effects. Recently, the bis-thiosemicarbazone family of copper 
complexes has been garnering attention for potential biological applications with minimal 
side effects.38 
 The two most prominent bis-thiosemicarbazone complexes are 1 and CuGTSM. 
Both have been evaluated for in vivo applications with 1 seeing more use as a diagnostic 
tool for hypoxia imaging27-31 and CuGTSM as a therapeutic.38 The key difference of these 
two complexes lies in their backbone, which ultimately effects their CuII/I reduction 
potential with CuGTSM being 160 mV more anodic.38 The ability to tune the reduction 
potential of these compounds allows for the exploitation of the different redox 
environments of cancer cells in contrast to healthy cells. Radiolabeled 64Cu- and 62Cu-
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ATSM have been shown to selectively remain in hypoxic tumor cells for improved 
imaging. The ease of modular synthesis had led to a variety of BTSC complexes being
 synthesized.7,13,15-18,20-21,40 A prime example of this is the modification of the ligand 
framework to incorporate a small peptide sequence to enhance imaging. This synthetic 
methodology could be employed to enhance cell type specificity and uptake with the 
correct amino acid sequence.33 Further, Que and co-workers designed a novel imaging 
agent that eliminates the employment of radiolabeled copper and makes use of 19F MRI 
imaging.32  
 The exploitation of CuGTSMs more anodic CuII/I couple as a cancer therapeutic 
has led to an increase in studies on BTSCs and anti-cancer applications.11 Recently the 
development of cyclized derivatives, the condensation of 4-methyl-4-
phenylthiosemicarbazide with glyoxal, were evaluated.39 Interestingly, these compounds 
revealed a structure-activity relationship that suggested the mechanism of activity 
involving DNA strand breaking. Expanding upon the structure activity relationship 
revealed by the 4-methyl-4-phenylthiosemicarbazide derivatives,39 Palma et al. showed 
that cytotoxicity could be increased with incorporation of cyclic amines even in Cu BTSCs 
with similar CuII/I potentials to those observed for 1.63 Further, removing the hydrogen-
bond donor ability of the pendant amine group has been shown to increase efficacy by 
preventing the system from being a substrate for MDR-1.65 
 All of these routes to improve the activity of 1 stem from modification of the 
pendant amine functional group. The recently synthesized alkoxy CuATSM derivatives 
10-15 (Chapter 3) established that the structural components remained identical to the 1 
while the electrochemical properties were changed. This chapter reports the synthesis, 
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characterization, and electrocatalytic behavior of a series of hybrid M(II) (where M = Ni, 
Cu, and Zn) complexes derived from BTSCs, Scheme 5-1, for evaluation of anti-cancer 
properties. The ligands are obtained in high yields using readily available, inexpensive 
organic reagents according to literature methods. The resulting compounds have been 
characterized by NMR, FT-IR, and UV-vis spectroscopies, x-ray crystallography (18, 19, 
21, and 22), and cyclic voltammetry. 
 
Scheme 5-1. Synthesis and numbering of ligand and metal chelates. 
5.2 Results 
5.2.1 Synthesis and Characterization 
 A series of hybrid ligands (16 – 18) with variation in the alkoxy alkyl chain length 
of ethyl (16) and propyl (17) as well as incorporation of a phenyl group in the backbone 
(18). The ligands were complexed with the metals Cu(II) (19 – 21), Ni(II) (22 – 24), and 
Zn(II) (25 – 27). The ligands are obtained from bulk commodity chemicals. The synthetic 
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routes involves those previously described in Chapter 3 for the hydrazinecarbothioc acid 
O-ethyl ester, and slight modification from previous literature reports for the mono-keto-
thiosemicarbazide. Briefly, dropwise addition of dilute 4-methyl-3-thiosemicarbazide to a 
concentrated dione solution with rapid stirring results in the mono-condensed product that 
is isolated via filtration. This can then be condensed with the hydrazinecarbothioc acid O-
ethyl ester to yield the full ligand as depicted in Scheme 5-1.  
 The 1H NMR of 16, Figure 5-1, displays a combination of prototypical chemical 
shifts associated with BTSCs and the alkoxy ligands (4 – 9). Whereas the molecule is 
asymmetric, the backbone protons remain in similar magnetic environments and occur as 
a single peak at 2.17 ppm. The methyl protons from the pendant amine are observed as 
singlet at 3.00 ppm, while the methyl protons from the alkoxide moiety yield a singlet 
upfield at 1.28 ppm. The pendant amine proton is observed at 8.35 ppm, the iminio proton 
of the thiosemicarbazide side is at 10.21 ppm, and the imino proton of the alkoxide side 
displays the two chemical shifts of 11.31 ppm and 11.62 ppm (Chapter 3). The 13C NMR 
of 16, Figure 5-2, exhibits the chemical shift for the alkoxy carbon at 66.3. The alkyl peaks 
of the backbone carbons, –NHCH3, and CH3 from the ethyl alkoxide are observed in the 
peaks at δ 11.8 – 31.7. The C=N is present at 179.0 and the C=S at 152.5 and 147.9 
respectively. The 1H and 13C NMR of 17 and 18 are similar and can be found in the 
Appendix (Figures A40-A43).  
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Figure 5-1. 1H NMR of 16 in DMSO. 
 
 
Figure 5-2. 13C NMR of 16 in DMSO. Inset shows DMSO peak. 
 The FT-IR of 16 (Figure 5-3) is representative of the class of ligands with the 
remaining found in Appendix (Figures A44-A45). Notably, 16 displays a combination of 
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hallmark stretches of both BTSCs, two N–H stretches at 3382 and 3253 cm-1, and the 
previously synthesized alkoxy ligands, C–O at 1130 cm-1. Upon metalation with copper 
(19), Figure 5-3 B, the N–H stretch present at 3382 cm-1 is absent consistent with 
deprotonation of the imino hydrogen. However, an N–H stretch is observed at 3305 cm-1 
due to the presence of the pendant amine. The C–O stretch remains largely unaffected at 
1132 cm-1. Further, the addition of stretches at 846 and 782 cm-1are attributed to C–S and 
Cu–N bonds respectively. Similar stretches, such as the appearance of Ni–S/Ni–N and Zn–
S/Zn–N are observed in the remaining FT-IR spectra and can be found in the Appendix 
(Figures A46 – A51). 
 
Figure 5-3. FT-IR of 16 (A) and 19 (B) as powders. 
 When 16 is chelated with zinc (25) the 1H NMR (Figure 5-4) displays full 
deprotonation of the imino hydrogens with the absence of a peaks at 10.21 and 11.31/11.62 
ppm. This trend is consistent with the remaining zinc complexes (Figures A52-56). The 
nickel derivatives display a similar 1H NMR pattern, however in all nickel complexes a 
peak at 8.55 is present (Figures A57-A59). This is not attributed to the imino hydrogens as 
those are over 2 ppm downfield, and in the FT-IR (Figure 5-5) of 22 there is only one N–
H stretch. This peak is attributed to a small amount of residual acetic acid. 
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Figure 5-4. 1H NMR of 25 in DMSO. 
 
Figure 5-5. FT-IR of 22 as a powder. 
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 The electronic spectra of 19 – 27 were collected in acetonitrile, and all display two 
ligand to ligand charge transfer bands and one metal to ligand charge transfer band. The 
electronic spectra of the Cu complexes (19 – 21) are displayed in Figure 5-6. Compounds 
19 and 20 contain ligand to metal charge transfer bands at 477 and 473 nm respectively. 
The charge transfer band in 21 is redshifted by 346 cm-1 (8 nm) to 485 nm relative to 19. 
This redshift is observed within the higher energy ligand to ligand charge transfer values. 
The recorded ligand to ligand charge transfer band for 19 and 20 are observed at 248 and 
249 nm. For 21 this value is red shifted by 2,300 cm-1 relative to 19, to 263 nm. 
Interestingly, the lower energy band remains consistent in all complexes at a value of 309 
nm. The remaining electronic spectra of Ni (22 – 24) and Zn (25 – 27) can be found in the 
Appendix (Figures A60-A61). In both of these systems the redshift is observed for the 
phenyl derivative, 24 for the Ni and 27 for the Zn. In the Ni system, however, the high 
energy ligand to ligand charge transfer band remains similar with all occurring around 255 
nm. The lower energy band however has values of 329 and 330 nm for 22 and 23 
respectively, whereas 24 appears at 342 nm, a redshift of 1156 cm-1. Lastly, in the Zn 
complexes, all charge transfer bands of 27 are redshifted relative to 25 and 26. The ligand 
to ligand charge transfer bands are observed at 243 and 299 nm for 25 and the metal to 
ligand charge transfer occurring at 422 nm. However, in 27 the corresponding transfer 
bands occur at 269, 326, and 430 nm, redshift values of 3,978 cm-1, 2,770 cm-1, and 441 
cm-1. 
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Figure 5-6. UV-visible spectra of 19 (blue trace), 20 (red trace), and 21 (black trace) recorded in 
acetonitrile. 
5.2.1 HER Catalysis Evaluation 
We had previously established that 1, 3, and its ligand,10,34 are viable for proton 
reduction catalysts. As described in Chapter 3, substitution of the –NHMe groups of 1 with 
the –OMe of 10 results in a large anodic shift in the reduction potential. Such a shift could 
potentially lower the overpotential of these types of HER catalysts. To this end 10 was 
evaluated as a possible HER catalyst, but ultimately failed. The absence of HER activity 
was attributed to the first step of the mechanism of HER evolution of CuATSM, 
protonation. A ligand framework with electron withdrawing groups (EWG) can lower 
reduction potentials. However, the employment of these EWGs leads to a loss of basicity 
in the ligand framework. To rectify this situation, a hybrid ligand was developed in which 
one pendant group was –NHMe and one was –OEt. The complex was further modified by 
incorporation of a phenyl group in the backbone, 21. Under catalytic conditions 21 (blue 
trace), was found to produce hydrogen unlike 10 (red trace), Figure 5-7. Ultimately though 
21 did not produce H2 at a reasonable overpotential. To investigate this, spectrophotometric 
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titrations were employed. CuATSM was used as the standard since at this point it was the 
best performing CuBTSC HER catalyst. 
 
 
Figure 5-7. Comparison of 21 and 10 under catalytic HER conditions. 
 The dissolution of 1 in DMSO gave a red solution which then had its UV-vis 
recorded, Figure 5-8 top, black trace. Then triflic acid was added in sequential 30 μL 
aliquots, with spectrums recorded after each addition, Figure 5-8 (for clarity, only select 
total additions are shown). During the course of the titration a color change was observed 
from red to yellow, as indicated in the blue shift of the λmax from 480 to 460 nm. To ensure 
that the endpoint was reached, the corrected absorbance of 480 and 460 nm vs acid addition 
was plotted until a plateau was achieved, Figure 5-8 bottom. 
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Figure 5-8. Selected UV-Vis spectra of 1 during titration (top) Corrected absorbance vs additions 
of acid for 480 and 460 nm (bottom). 
This same experiment was perfomred for 21, Figure 5-9. As previously seen with 
1, there is a blue shift in the λmax, from 490 to 450 nm and an isobestic point is observed at 
460 nm. These observations lead to the conclusion that restoration of the amine moiety 
allowed for protonation. However, it is important to note the volume of acid requisite to 
reach the saturation point of 21 of 660 μL compared to that of 1 of 420 μL. This increase 
in acid addition is attributed again to the EWG of the alkoxy moiety leading to a decrease 
in overall basicity of the complex.  
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Figure 5-9. Selected UV-Vis spectra of 21 during titration (top) Corrected absorbance vs 
additions of acid for 490 and 450 nm (bottom). 
 
Work done by Jain et al.76 and others35 highlighted the potential for NiBTSC 
complexes as homogeneous HER catalysts. Notably, the first step in the HER mechanism 
of NiBTSCs is reduction, not protonation. This change in mechanism could potentially 
allow for the employment of stronger EWG’s without shutting down catalysis due to lack 
of basicity. These results lead to the use of NiATSM (2) as a parent compound, and 
synthesize 28 and 29 to investigate the effect of EWGs and electron donating groups (EDG) 
on heterogeneous HER catalysis, as described in Chapter 4. 
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5.2.1 Crystallography 
The solid state structures of 18, 19, 21, and 22 were determined by single crystal x-
ray diffraction. The copper complexes 19 and 21 crystallized as a dark orange needle and 
an orange plate, respectively, in the space group P-1. The nickel complex 22 crystalized as 
an orange plate in the space group P21/c. The ligand, 18, crystallized as a yellow prism in 
the space group P21/c. All four complexes crystallize without inclusion of solvent 
molecules. Crystallographic data and structural refinement details are listed in the Chapter 
2 Tables 2-3 to 2-4. 
The ORTEP95 representations of 18, 19, 21, and 22, Figure 5-10 (A-D), show that 
each metal lays in a square planar N2S2 donor environment. Selected bond distances and 
angles can be found in Table 5-1. The Ni–N and Ni–S bonds are different from that of the 
Cu–N and Cu–S bonds, with the former having the shorter bond lengths. However, within 
a metal class, the chelation bonds are not statistically different. The Cu–N bond distances 
of 1.959(2) and 1.967(2) for 19 are not different from those of CuATSM96 with 
corresponding lengths of 1.9584(16). This is also in good agreement with the Cu(II) 
compounds reported in Chapter 3.82 The Cu-S bonds, of 2.2529(7) and 2.2795(7) for 21, 
and 2.2453(5) for that of CuATSM are also statistically equivalent. The same structural 
trend is observed for the Ni(II) complexes with the Ni–N and Ni–S bond lengths for all 
compounds. Within the ligand framework, all bond distances across the series regardless 
of the chelated metal are statistically equivalent. They are consistent with a conjugated π-
system of alternating single and double bonds. The bond distances in 19 of S1–C5, N1–
N2, and C1–C2, are 1.761(3), 1.362(3), and 1.477(3) Å, respectively, which are typical of 
single C–S, N–N, and C–C bonds. The remaining ligand framework bonds N1–C1 and N2–
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C5 are shorter with distances of 1.293(3) and 1.318(3) Å respectively, consistent with C=N 
bond character. The sum of the four bond angles about the Cu is 358.33(0.12) °.  
 
Figure 5-10. ORTEP95 representations of 18(A), 19 (B), 21 (C), and 22 (D). 
All three chelates are rigorously planar. For complex 22, the best fit plane of all 18 
non-hydrogen atoms has a standard deviation of ±0.128 Å with the largest deviation being 
±0.326 Å for C9. For 19, the best fit plane for all 18 non-hydrogen atoms has a standard 
deviation of ±0.067 Å with the largest deviation of ±0.116 Å for C9. Excluding the phenyl 
ring in 21 (C5-C9) the best fit plane for all 18 non- hydrogen atoms has a standard deviation 
of ±0.137 Å with the largest deviation of ±0.329 Å for C12 (C7). The phenyl ring atoms of 
C5-C9 are planar within the ring, with a standard deviation of ±0.013 Å with the largest 
deviation of ±0.01662 Å for C5. The phenyl ring within the free ligand exhibits the same 
phenomenon with a standard deviation of ±0.013 Å and with the largest deviation of 
±0.01662 Å for C5.  
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Table 5-1. Selected bond distances and angles for 18, 19, 21, and 22. 
Bond Distance 18 19 21 22 
M–N1 N/A 1.967(2) 1.9755(14) 1.868(3) 
M–N3 N/A 1.959(2) 1.9590(13) 1.859(2) 
M–S1 N/A 2.2529(7) 2.2725(4) 2.1554(8) 
M–S2 N/A 2.2795(7) 2.2871(5) 2.1740(8) 
S1–C5 (C10)a 1.6736(13) 1.761(3) 1.7584(17) 1.760(3) 
S2–C6 (C11)a 1.6568(14) 1.758(3) 1.7376(16) 1.753(3) 
O1–C6 (C11)a 1.3160(13) 1.332(3) 1.3339(19) 1.334(4) 
N1–C1 1.2898(17) 1.293(3) 1.298(2) 1.303(4) 
N1–N2 1.3660(15) 1.362(3) 1.3611(19) 1.376(4) 
N2–C5 (C10)a 1.3672(17) 1.318(3) 1.319(2) 1.319(4) 
N5–C5(C10)a 1.3251(18) 1.338(3) 1.331(2) 1.338(4) 
C1–C2 1.4778(18) 1.477(3) 1.472(2) 1.473(4) 
C1–C3 1.496(2) 1.492(4) 1.492(2) 1.488(4) 
Bond Angles     
N3–M–N1 N/A 80.31(9) 79.68(6) 83.38(11) 
N1–M–S1 N/A 84.58(6) 83.31(4) 87.18(8) 
N3–M–S2 N/A 84.59(6) 84.49(4) 87.27(8) 
S1–M–S2 N/A 108.85(3) 111.359(16) 102.15(3) 
a) Numbers are different due to presence of benzene rings in 18 and 21. 
5.2.2 Electrochemistry 
 The importance of electrochemical properties of the BTSC complexes has been 
well documented. The cyclic voltammograms of the free ligands and metal chelates can be 
found in Figure 5-11 (A-D). Notably, both the Cu and Ni derivatives display quasi-
reversible events in their respective voltammograms. This is in contrast to the Zn and free 
ligand voltammograms, which display two irreversible reductions. As the chelated metal 
is varied, a periodic trend is observed with Cu have the most anodic events, followed by 
Ni, then Zn, and lastly the free ligand. The CuII/I couple is 0.57 - 0.63 V more anodic than 
that of the first redox event of the Ni class (ligand centered) and 1.28 - 1.36 V more anodic 
than the Ni II/I couple, Table 5-2. The Ni ligand centered reduction is 0.41 – 0.42 V more 
anodic than that of the first Zn reduction and 0.55 - 0.68 V than the first free ligand 
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reduction. Lastly the Zn stabilizes the ligand centered reductions by 0.14 - 0.26 V and 0.47 
- 0.56 V more anodic than the respective free ligand events. 
 
Figure 5-11. Cyclic voltammograms over lays of ligand framework 16 (red trace) and 18 (blue 
trace) with their respective chelates copper (A), nickel (B), zinc (C) and, free ligand (D).  
 
Across the ligand series, there is a clear effect of electron donor ability from the R 
groups on reduction potential. The alkyl extension of R2 from ethyl to propyl resulted in a 
minimal or no effect on reduction potential.82  This is exemplified in the 0.01 V shifts for 
Cu complexes 19 and 20, and first free ligand reduction, 16 and 17, event and the 0.03 V 
shift for the second Zn reduction in 25 and 26. All other redox couples were unchanged by 
alkyl extension.  However, the incorporation of a phenyl group in R1 caused a significant 
anodic shift in reduction potential for all compounds. For the Cu complexes 19 and 21, a 
0.08 V anodic shift is observed. The most dramatic effect on the reduction potential is for 
the free ligand 16 and 18, which exhibited a 0.17 V anodic shift in potential. 
In comparison with the previously reported ATSM and GTSM the copper 
derivatives are found to lay more anodic than both, with potentials of -1.11 and -0.950 V 
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respectively. This indicates that these compounds could have potential use in anti-cancer 
applications given the accessibility of their reduction potentials. This clearly demonstrates 
the ability to tune the reduction potential via the incorporation of an alkoxy moiety on only 
one side of the ligand framework cause the potential to lay in between that of the bis-amine 
and bis-alkoxy derivatives. 
Table 5-2. E1/2 values for 16-27 (V) vs Fc+/Fc 
Ligand Cu(II/I) NiL/NiL- Ni(II/I) ZnL/ZnL- ZnL-/ZnL2- L/L- L-/L2- 
16 -0.930 -1.56 -2.21 -1.98 -2.37 -2.23 -2.70 
17 -0.940 -1.56 -2.22 -1.98 -2.40 -2.24 -2.70 
18 -0.850 -1.42 -2.12 -1.83 -2.22 -1.97 -2.53 
 
5.2.3 Cell line Evaluation 
To investigate any potential therapeutic effects the compounds may have for anti-
cancer, they were screened against the cancer cell line A549 and its healthy counterpart 
IMR-90. This work was conducted in collaboration with Dr. Paula Bates at the University 
of Louisville Medical School. All MTT assay experiments were performed by Dr. Sarah 
Andres. The MTT assay of ligand system 16, 17, and 18 are shown in Figure 5-12 and 5-
13 (A and B), respectively. Since all compounds display redox activity, redox activity alone 
does not lead to enhanced therapeutic potential. The Cu complexes 19, 20, and 21 have 
respective GI50 values of 0.082, 0.29, and 0.065 μM for A549, compared to >2.0, >2.0, 
and 1.3 μM of the IMR-90 cells line, Table 5-3. The nickel derivatives, 22, 23, and 24, 
display larger GI50 values for both A549 and IMR90 cell lines, with no clear trend in 
selectivity. The difference in performance for the Cu and Ni complexes is attributed to the 
relatively accessible reduction potential of the Cu complexes as compared to Ni, Table 5-
2. With the copper chelates displaying substantially more anodic potentials, the Cu(II) core 
of 19 – 20 are capable of being reduced to Cu(I) intracellularly and thus have high 
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bioactivity. This selectivity trend based on reduction potential not only explains the 
difference between our copper and nickel compounds but also previously reported ATSM 
derivatives, appendix Figure A62. It is clear that when both cell types are treated with 
CuATSM, a larger dose is required to see the anti-proliferation effects with the A549 and 
IMR90 cells. This result shows that even with the same chelated metal, Cu, the CuII/I 
reduction potential is crucial in creating a selective therapeutic. 
Table 5-3. GI50 values for 16-27. 
Ligand/Cell line GI50 (μM) Cu Ni Zn Ligand 
16 A549 0.082 3.0 0.59 0.60 
16 IMR90 >2.0 5.3 0.68 1.1 
17 A549 0.29 10.1 0.45 0.47 
17 IM90 >2 13 0.52 >2 
18 A549 0.065 37 0.055 0.091 
18 IMR90 1.3 >100 1.1 >2 
 To examine any potential trans-metallation and structural ligand effects 
both the free ligand and Zn complexes were evaluated for their potential therapeutic 
capabilities. It is evident from the MTT assays that the ligand framework can play a key 
role in biological activity. The free ligands 16 and 17 and Zn complexes 25 and 26 show 
lower therapeutic potential relative to their Cu analogues. The compounds 16, 17, 25, and 
26 display improved therapeutic capabilities when they are compared to their 
corresponding Ni analogues. This is not the case however, for the free ligand 18 and Zn 
complex 27. The MTT assay profiles are nearly identical to their copper analog 21. This 
degree of similarity could suggest potential trans-metallation is occurring in the growth 
media and the copper complex is being generated in situ and is the active species. Should 
this have been the case then both 25 and 26 would have displayed similar profiles to their 
copper analogs, which they do not. Interestingly, all the free ligands 16 – 18 display similar 
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profiles to their Zn complexes 25 – 27. Thus any difference in the activity of the ligands 
and Zn compounds can be attributed to a structural effect. The major structural difference 
of 18 compared to 16 and 17 is the presence of the phenyl group in the backbone. It should 
be noted that 18, was not purified from the crude product, which may be contaminated with 
starting material, so some activity could be from the unreacted starting material. It is also 
possible that there was a difference in copper concentration in the culture media from the 
different lots of media employed during screening, leading to more extensive 
transmetallation in the evaluation of 18 and 27. To ensure all compounds are evaluated 
under identical copper concentrations, the media needs to be scrubbed with 
tetrathiomolybdate. 
  Interestingly, the phenyl structural component does not lead to activity in 24. The 
lack of activity of 24 can be attributed to its d-electron count. Compounds 21, and 27 after 
reduction, are d10 thus are kinetically labile however, even after reduction, 24 is only d9. In 
the kinetically labile 21 and 27, the metal is proposed to dissociate leaving the active ligand 
which has more conformation flexibility than the metal complexes. In 24 however, the 
ligand framework is forced to remain in the square planar chelate system and thus is not 
capable of achieving the required orientation for inhibition.  An interesting possibility for 
a mechanism of action is that the ligand is the biologically active material and the metal 
plays the role of chaperone. If reduction potential was the dominant factor for potency, 
then it would be expected that 21 would display substantially higher activity compared to 
its more cathodic analogs 19 and 20. Given the similarity of their GI50 values, this is most 
likely not the case. However, if bioactivity was predominantly based on structure, then the 
nickel derivatives 22 – 24 would be as active. The ligand itself also does not display equal 
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or better activity to the copper derivatives. This led to the hypothesis that the square planar 
nature of the metal chelate enhances cellular uptake and the reduction potential then allows 
for selectivity. After reduction in the desired cell, the metal can be released leaving the free 
ligand to inhibit cellular respiration (Scheme 5-2).  
 
Figure 5-12. MTT assay results of cell lines A549 (top) and IMR90 (bottom) for the free ligand 
16 (black trace), Cu complex 19 (red trace), Ni complex 22 (green trace) and Zn complex 25 
(blue trace).  
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Figure 5-13. MTT assay results of cell lines A549 (top) and IMR90 (bottom) for the free ligands 
17 (A) and 18 (B) (black trace), Cu complexes 20 (A) and 21 (B) (red trace), Ni complexes 23 (A) 
and 24 (B) (green trace) and Zn complexes 26 (A) and 27 (B) (blue trace). 
 
Scheme 5-2. Proposed mechanism of action for anti-cancer effects from copper chelates. 
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5.2.4 National Cancer Institute 60 Cell Line 
Compounds 19 and 21 were sent to the NIH to be examined with the National 
Cancer Institute 60 Cell Line (NCI-60) screening. The NCI-60 is a panel of a variety of 
carcinogenic cell lines used to examine compounds for their anti-cancer properties. 
Notably, the diversity of the carcinogenic cell lines employed allows for the comparison of 
tested compounds against known anti-cancer agents to identify a possible mechanism of 
action. The results, shown in Figure 5-14 and 5-15 respectively, show that these 
compounds are active against most of the tested cell lines with similar profiles, and in most 
cases were cytotoxic. It should be noted however that both compounds were completely 
inactive against all leukemia lines. The stark contrast in activity may be attributed to the 
difference in the types of cancer. The compounds were most active against cell lines 
derived from solid tumors, whereas leukemia is not. The cell lines derived from solid 
tumors may provide a more hypoxic environment that would allow the redox active 
compounds to operate as anti-cancer agents, whereas a lack of a hypoxic environment, such 
as in the leukemia cells, would prevent any cytotoxicity via redox active compounds. It 
should be noted that the cell lines derived from solid tumors are not grown under a hypoxic 
environment. Also, several tumor cell lines displayed resistance to our compounds. This 
resistance has yet to be fully understood, but elucidation of their differences relative to the 
rest of the solid tumors will provide valuable insight into the mode of action of these 
compounds. 
5.3 Conclusions 
 A new ligand system and the corresponding nickel, copper and, zinc chelates were 
successfully synthesized. Incorporation of the alkoxy moiety allows tuning of the 
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reduction potential to achieve values relevant for biological activity. Further, the effect of 
structure on activity was demonstrated with the improved potency of the phenyl 
derivative. The NCI-60 screening demonstrates that this new class of chelates are active 
against a wide variety of cell lines however, a clear mechanism of action is yet to be 
elucidated.  
 
Figure 5-14. NCI-60 profile of 19 displaying the percent growth relative to the control. 
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Figure 5-15. NCI-60 profile of 21 displaying the percent growth relative to the control.  
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CHAPTER VI 
 CONCLUSIONS 
The progress of BTSC’s in therapeutics and diagnostics prompted the synthesis of 
alkoxy analogues to explore a new functional group and its effect on structure and 
reduction potentials. A total of six new ligands (4 – 9) and their copper chelates (10 – 15) 
were synthesized from bulk commodity chemicals with decent yields. Importantly the 
synthetic route uses alcohols, both primary and secondary alcohols for the starting material, 
which enables a variety of derivatives to be synthesized. The investigation into the structure 
revealed that all of the copper chelates (10 – 15) were analogous to CuATSM. Single 
crystal X-ray crystallography showed that these chelates are rigorously planar, a crucial 
facet to be capable of entering cells. Further the relative energy of the d-orbital manifold 
was found to be similar. However, the electrochemistry revealed a substantial anodic shift 
in the CuII/I potential of ~250 mV when comparing 10 to CuATSM. This large shift even 
puts these systems more anodic than CuGTSM, which makes them interesting as possible 
drug candidates. The observed shift allows for greater tuning of the electrochemistry of 
these types of ligand frameworks, which has been shown to be important to the function of 
the BTSC class. However, by removing the two hydrogen bond donors that are present in 
the ATSM framework, the solubility was significantly altered. These alkoxy systems could 
only be dissolved in halogenated organic solvents, like DCM, effectively neutralizing any 
potential therapeutic properties that require dissolution prior to treatment. If a suspension 
or oral gavage could be employed these systems can be evaluated for their drug like 
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properties. It should be noted that the reduction potential of these systems is only 
modulated within a three carbon chain length, meaning effectively the solubility could be 
restored with a functionalized alcohol without effecting the redox couple. One possible 
synthetic route that could be explored to implement these more exotic alcohols is trans-
esterification much like Que and co-workers demonstration of the applicability of trans-
amination. Further the alkoxy class of ligands failed to act as HER catalysts due to the poor 
basicity of the ligand framework. This result demonstrated the limit of electron 
withdrawing that future investigations could employ to attempt to minimize the 
overpotential of such catalysts, a central step in rational design. 
The data from the alkoxy systems (4 – 15) prompted the restoration of the pendant 
amine on one side of the ligand to create a hybrid system. Notably, this improved solubility, 
catalysis performance, and cathodically shifted the CuII/I potential relative to the alkoxy 
functionality. Ultimately though, the hybrid system failed to perform adequately as an HER 
catalyst. However, this again showed that while this system was capable of producing H2, 
the electron withdrawing functional group prevents sufficient performance, leading to the 
focus of improvement on traditional BTSC complexes. 
Three Ni BTSCs were immobilized on a glassy carbon electrode for heterogeneous 
HER catalysis. Catalysts 2 and 28 displayed similar HER performance, whereas 29, was 
substantially different. This difference in performance is attributed to the solid state 
intermolecular packing. Single crystal X-ray crystallography provided essential insight to 
how the complexes interacted in the solid state. The two rigorously planar systems, 2 and 
28 behaved and packed in nearly identical fashions with closer intermolecular contacts less 
than 3.60 Å. The fluorinated groups of 29 prevented the molecules from forming close 
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contacts with one another and the electrode surface. Thus inhibiting electron transport and 
leading to larger overpotentials and charge transfer resistance. Whereas the planar 
derivatives 2 and 28 can undergo dynamic re-arrangement during reductive cycling to form 
a better contact to the electrode surface that improves overall performance. Raman 
spectroscopy further revealed that 29 was lost from the electrode surface during reductive 
cycling.  
The significant improvement after conditioning is vital to further enhancing overall 
catalyst performance of these systems. Both 2 and 28 display remarkable stability on the 
electrode surface and retained activity after extended cycling. The remarkable longevity 
without a covalent linker is crucial in development of these systems as the dynamic 
rearrangement is necessary for catalyst improvement and would be impossible if covalently 
linked to the electrode surface. A potential improvement could be made by incorporation 
of a molecule that facilitates electron transfer to further lower the charge transfer resistance 
for 2 and 28. For 29, the poor packing and lack of stability prevented an adequate analysis 
of electron withdrawing groups on heterogeneous catalysis for NiBTSCs. Thus synthesis 
of a novel derivative that can form close contacts and longevity on the electrode surface as 
displayed by 2 and 28, is paramount to further catalyst development.  
The hybrid system failed for HER catalysis but the anodically shifted CuII/I 
reduction potential and improved solubility due to restoration of the hydrogen bond donor 
amine, indicated potential anti-cancer properties. A series of ligands (16 – 18) were 
synthesized and chelated with metals Cu (19 – 21), Ni (22 – 24), and Zn (25 – 27) to give 
a total of 12 new compounds, which were each screened for therapeutic potential via an 
MTT assay. The results of the MTT assay point to the copper derivative being the most 
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potent and selective between carcinogenic cells and healthy. Interestingly these results 
show that while reduction potential is crucial for activity and selectivity, there is an 
emerging importance of structure. The more active systems of the copper, zinc, and free 
ligand are deemed capable of becoming the free ligand (or are already) when in the cell. 
The copper system is capable of being reduced to Cu(I) which is kinetically labile, like 
zinc. Notably, the reduction potential of the zinc system is not capable of being achieved 
intracellularly, meaning the activity observed from zinc is purely structural. The same 
argument however does translate to the nickel derivative. The exception is that even if 
reduction was achieved for the nickel system, it would still be kinetically inert, so only 
structural effects of the chelate are observed. This explains why the zinc and free ligand 
have such similar profiles and the nickel performs poorly. Further, this explains the 
enhanced selectivity and potency of the copper complexes. The chelated form allows for 
facile diffusion across membranes, and the copper is only released when reduced. 
Additionally, if the reduction potential was the dominant factor in effectiveness, then 21 
should show a significant increase in performance relative to 19. Although 21 does display 
a minor decrease in concentration required to achieve a GI 50, it is minimal considering 
the larger anodic shift. Additionally, 19 and 21 were screened against the 60 cell lines in 
the NCI 60 assay. Both systems exhibited a similar profile with high activity and 
cytotoxicity against a wide variety of cell lines derived from solid tumors. The leukemia 
cell lines remained unaffected by these complexes, providing valuable insight that can help 
elucidate a clear mechanism. These results are the first to demonstrate that the structure of 
the ligand and the CuII/I redox couple together lead to selectivity and activity. This will 
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allow for better design of new systems to exploit the metal as the chaperone, but tuning the 
ligand to act as the drug. 
 Further, it has been demonstrated in the literature that BTSCs are substrates for 
MDR-1 due to their hydrogen bond donor pendant amine. It is plausible that tuning the 
reduction potential with the alkoxy functionality led to enhanced potency of these systems 
via inhibiting specificity for MDR-1. A binding affinity assay comparing ATSM to the 
hybrid could prove this, and thus further render the previous alkoxy complexes, 10 – 15 
desirable for therapeutics with lack of hydrogen bond donors and more anodic CuII/I 
potentials. However, solubility needs to be increased without restoration of hydrogen bond 
donors so as not to make the modified system a substrate for MDR-1. 
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APPENDIX 
 
Figure A1. H2ETCB (5) 
1H NMR 
(C2D6NO, 400 MHz) δ 1.51 (br, 6H) 2.46 (br, 4H) 4.74 (s, 6H) 11.51 (s, 1H) 11.92 (s, 
1H). 
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Figure A2. H2PTCB (6) 
1H NMR 
(CDCl3, 400 MHz) δ 0.99 (t, 6H, J=7.28) 1.84 (quin, 4H, J=6.24) 2.13 (s, 6H) 4.55 (t, 
4H, J=6.22) 9.15 (s, 2H). 
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Figure A3. H2PTCB (6) 
13C NMR 
(CDCl3, 100 MHz) δ 9.78, 10.3, 21.9, 29.7, 187.6 
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Figure A4. H2
iPTCB (7) 1H NMR  
(CDCl3, 400 MHz) δ 1.41 (br, 12H) 2.12 (s, 6H) 5.63 (br, 2H) 9.10 (s, 2H). 
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Figure A5. H2
iPTCB (7) 13C NMR 
 (CDCl3, 100 MHz) δ 9.9, 21.6, 148.3, 186.7. 
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Figure A6. H2OTCB (8) 
1H NMR 
(CDCl3, 400 MHz) δ 0.87 (br, 6H) 1.28 (m, 16H) 1.43 (br, 4H) 1.81 (br, 4H) 2.13 (s, 6H) 
4.59 (br, 4H) 9.12 (s, 2H). 
  
127 
 
 
Figure A7. H2OTCB (8) 
13C NMR 
(CDCl3, 100 MHz) δ 14.1, 22.6, 25.8, 28.4, 29.1, 31.7. 
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Figure A8. H2ETCH (9) 
1H NMR 
(CDCl3, 400 MHz) δ 1.08 (br, 6H) 1.41 (br, 6H) 2.63 (br, 4H) 4.63 (br, 4H) 9.23 (br, 2H). 
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Figure A9. H2ETCH (9) 
13C NMR 
(CDCl3,100 MHz) δ 10.49, 14.02, 17.01, 68.87, 152.27, 187.47. 
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Figure A10: FT-IR of H2ETCB (5) 
Infrared spectrum of the H2ETCB ligand as a powder (ATR)  
 
 
Figure A11: FT-IR of H2PTCB (6) 
Infrared spectrum of the H2PTCB ligand as a powder (ATR)  
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Figure A12: FT-IR of H2
iPTCB (7) 
Infrared spectrum of the H2
iPTCB ligand as a powder (ATR)  
 
 
Figure A13: FT-IR of H2OTCB (8) 
Infrared spectrum of the H2OTCB ligand as a powder (ATR)  
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Figure A14: FT-IR of H2ETCH (9) 
Infrared spectrum of the H2ETCH ligand as a powder (ATR)  
 
 
Figure A15: FT-IR of Cu(ETCB) (11) 
Infrared spectrum of the Cu(ETCB) ligand as a powder (ATR)  
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Figure A16: IR Spectrum of Cu(PTCB) (12) 
Infrared spectrum of Cu(PTCB) as a powder (ATR) 
 
 
Figure A17: IR Spectrum of Cu(iPTCB) (13) 
Infrared spectrum of Cu(iPTCB) as a powder (ATR) 
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Figure A18: IR Spectrum of Cu(OTCB) (14) 
Infrared spectrum of Cu(OTCB) as a powder (ATR) 
 
 
Figure A19: IR Spectrum of Cu(ETCH) (15) 
Infrared spectrum of Cu(ETCH) as a powder (ATR) 
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Figure A20. Cu(ETCB) (11) UV-Vis in dichloromethane 
 
 
Figure A21. Cu(PTCB) (12) UV-Vis in dichloromethane 
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Figure A22. Cu(iPTCB) (13) UV-Vis in dichloromethane 
 
 
 
Figure A23. Cu(OTCB) (14) UV-Vis in dichloromethane 
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Figure A24. Cu(ETCH) (15) UV-Vis in dichloromethane 
 
 
Figure A25. Cu(MTCB) (10) EPR on powder at room temperature 
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Figure A26. Cu(ETCB) (11) EPR on powder at room temperature 
 
 
 
Figure A27. Cu(iPTCB) (13) EPR on powder at room temperature 
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Figure A28. Cu(OTCB) (14) EPR on powder at room temperature 
 
 
Figure A29. Cu(ETCH) (15) EPR on powder at room temperature 
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Figure A30. Cyclic voltammogram of 11 in DCM at 200 mV/s 
 
 
Figure A31. Cyclic voltammogram of 12 in DCM at 200 mV/s 
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Figure A32. Cyclic voltammogram of 13 in DCM at 200 mV/s 
 
 
Figure A33. Cyclic voltammogram of 14 in DCM at 200 mV/s 
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Figure A34. Cyclic voltammogram of 15 in DCM at 200 mV/s 
 
 
Figure A35. FTIR of 28 as a powder (ATR) 
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Table A3. Parameters obtained by fitting frequency response analysis (FRA) data to 
simulated RCW circuit 
Zview software179 was used to fit data. Q is the magnitude of the CPE, Rc is the charge 
transfer resistance, Rs is approximate solution resistance, n is the CPE exponent, and C is 
the capacitance. Capacitance values were calculated using 𝐶 = 𝑅𝑐
1−𝑛
𝑛
 ∗ 𝑄
1
𝑛.180-184 
GC 1 2 3 
# 
Cycle
s 
0 300 1000 0 200 1000 0 1000 1500 
Q (F 
sn-1) 
2.43E-
6 
4.52E-
6 
4.46E-
6 
2.63E-
6 
6.10E-
6 
6.33E-
6 
2.24E-
6 
1.75E-
6 
1.73E-
6 
Rc 
(Ω) 
25099 270 374 18843 158 374 34518 34049 45793 
Rs 
(Ω) 
26.22 20.12 17.99 16.80 15.09 13.9 7.24 5.37 5.78 
N 0.908 0.929 0.913 0.916 0.893 0.864 0.893 0.899 0.896 
C (F) 1.83E-
6 
2.71E-
6 
2.43E-
6 
2.00E-
6 
2.65E-
6 
2.49E-
6 
1.65E-
6 
1.27E-
6 
1.29E-
6 
χ2 0.0001
5 
0.0012
1 
0.0014
1 
0.0007
2 
0.0005
7 
0.0005
7 
0.0003
0 
0.0031
3 
0.0025
2 
 
 
Figure A36. Nyquist plots showing the effects of reductive cycling from 0 to -0.8 V vs. 
RHE at 50 mV/sec on the impedance of GC-1. 
Solid traces represent fitted impedance data, while dotted traces represent actual data. (A) 
Nyquist plot showing impedance at 0 cycles (before any reductive cycling) and after 300 
cycles (peak activity, in small frame). (B) The same data as in (A), but with axes scaled 
down to show impedance after 300 cycles in greater detail. (C) Comparison of Nyquist 
plots for GC-1 after 300 cycles and 1000 cycles. 
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Figure A37. Nyquist plots showing the effects of reductive cycling from 0 to -0.8 V vs. 
RHE at 50 mV/sec on the impedance of GC-2. 
Solid traces represent fitted impedance data, while dotted traces represent actual data. (A) 
Nyquist plot showing impedance at 0 cycles (before any reductive cycling) and after 200 
cycles (peak activity, in small frame). (B) The same data as in (A), but with axes scaled 
down to show impedance after 200 cycles in greater detail. (C) Comparison of Nyquist 
plots for GC-2 after 200 and 1000 cycles. 
 
 
Figure A38. Nyquist plots showing the effects of cycling from 0 to -0.8 V vs. RHE at 50 
mV/sec on the impedance of GC-3. 
Solid traces represent fitted impedance data, while dotted traces represent actual data. (A) 
Comparison of Nyquist plots for GC-3 at 0 cycles (before any reductive cycling) and 
after 1000 cycles. (B) Comparison of Nyquist plots for GC-3 after 1000 and 1500 cycles. 
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Figure A39. Tafel slope as a function of number of cycles for each modified glassy 
carbon electrode. 
 
 
Figure A40. 1H NMR (400 MHz) of 17 in DMSO-D6. 
δ 0.94 (br, 3H) 1.70 (br, 2H), 2.11 and 2.19 (s/br, 6H) 3.00 (s, 3H) 4.41 (br, 2H) 8.43 
(s,1H) 10.25 (s, 1H) 11.35 and 11.63 (s, 1H) 
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Figure A41. 13C NMR (100 MHz) of 17 in DMSO-d6. 
δ 10.8, 22.0, 31.7, 179.0 
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Figure A42. 1H NMR (400 MHz) of 18 in DMSO-d6. 
Contaminated with starting material, as evidenced by peaks at 2.93 and 2.06 
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Figure A43. 13C NMR (100 MHz) of 18 in DMSO-d6. 
Contaminated with starting material. 
 
 
Figure A44. FT-IR of 17 as a powder (ATR) 
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Figure A45. FT-IR of 18 as a powder (ATR) 
 
 
Figure A46. FT-IR of 20 as a powder (ATR) 
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Figure A46. FT-IR of 21 as a powder (ATR) 
 
 
Figure A47. FT-IR of 23 as a powder (ATR) 
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Figure A48. FT-IR of 24 as a powder (ATR) 
 
 
Figure A49. FT-IR of 25 as a powder (ATR) 
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Figure A50. FT-IR of 26 as a powder (ATR) 
 
 
Figure A51. FT-IR of 27 as a powder (ATR) 
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Figure A52. 13C NMR (100 MHz) of 25 in DMSO-d6, inset shows DMSO. 
δ 14.2, 14.9, 64.0, 110.0 
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Figure A53. 1H NMR (400 MHz) of 26 in DMSO-d6. 
δ 0.92 (t, 3H) 1.66 (br, 2H) 2.20 (s,3H) 2.22 (s,3H) 2.85 (s,3H) 4.21 (br,2H)7.48 (s, 1H). 
Methanol present, peaks at 3.16 and 4.08.  
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Figure A54. 13C NMR(100 MHz) of 26 in DMSO-d6, inset displays the DMSO. 
δ 10.9, 14.9, 22.3, 69.7, 110.0 
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Figure A55. 1H NMR (400MHz) of 27 in DMSO-d6. 
δ 1.14 (t, 3H) 2.03 (s, 3H) 2.87 (s,3H) 4.08 (br, 2H) 7.45 (br, 5H) 7.61 (s, 1H) 
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Figure A56. 13C NMR (100MHz) of 27 in DMSO-d6. 
δ 14.8, 16.2, 110.0, 128.4, 129.5, 129.7, 132.9 
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Figure A57. 1H NMR (400 MHz) of 22 in DMSO-d6. 
δ 1.21 (t, 3H) 2.00 (s, 6H) 2.81(s, 3H) 4.20 (br, 2H) 8.03 (s, 1H)  
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Figure A58. 1H NMR (400 MHz) of 23 in DMSO-d6. 
δ 0.87 (t, 3H) 1.59 (br, 2H) 2.01 (br, 6H) 2.81 (s, 3H) 4.12 (br, 2H) 8.02 (s, 1H) 
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Figure A59. 1H NMR (400 MHz) of 24 in DMSO-d6. 
δ 1.12 (t, 3H) 1.80 (s, 3H) 2.85 (s, 3H) 7.46 (br, 5H) 8.19 (s, 1H) 
 
 
 
Figure A60. Electronic spectra of Ni complexes 22 (blue trace), 23 (red trace), and 24 
(black trace) in acetonitrile 
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Figure A61. Electronic spectra of Zn complexes 25 (blue trace), 26 (red trace), and 27 
(black trace) in acetonitrile 
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Figure A62. MTT assay results of cell lines A549 (top) and IMR90 (bottom) for the free ligand 
H2ATSM (black trace), CuATSM (red trace), Zn complex (blue trace), and NiATSM (green 
trace).
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2011 – 2013  Chemistry Tutor  General and Organic Chemistry 
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Professional Memberships 
2011 – Present  American Chemical Society 
Languages 
Spanish (Limited working proficiency, ILR level 2) 
Chinese (Elementary proficiency, ILR Level 1) 
Undergraduate Student Mentorship  
1. Joel Reihmer (NSF-REU student) Summer 2014 
2. Alan Weihe Spring & Summer 2016  
3. Maryssa Becker, Spring 2018 
Previous Employment 
Dunkin Donuts/Baskin Robbins, Glastonbury, CT   05/2011 – 08/2011 
Crew Member 
 Greeted customers in a friendly manner 
 Prepared and served beverages, ice cream specialties and various food items  
 Delivered fast and prompt service 
 Accurately handled cash for purchased food items 
 Maintained clean environment by sweeping, mopping and removing garbage 
 
Muscular Dystrophy Association, Glastonbury, CT   06/2010 – 08/2010 
Volunteer for Local Agency 
 Assisted in charity fundraising event by taking inventory of sponsoring signs, selling 
raffle tickets, and distributing tokens of appreciation 
 Organized mass mailings regarding upcoming events and fundraisers, and 
notification of outstanding donations 
  
Ted’s Supermarket, Hebron, CT     06/2008 – 08/2008 
Grocery Bagger 
 Accommodated customers by bagging groceries and loading into their cars 
 Organized stocked shelves 
 Closing duties included putting meats in freezer 
Other Activities   
Marist College: Treasurer of Resident Housing Council, Tutor, Intramural Soccer, Booster Club,  
Habitat for Humanity, Marist International Students Club, ACS Club 
 
East Catholic High School: Jazz Band, Soccer Team, Indoor & Outdoor Track Teams,  
Cross Country Team 
 
Marlborough Soccer Club 
 
 
 
 
